Tricyclic derivatives and their preparation and use

Tricyclic derivatives are developed as autotaxin inhibitors to address the need for effective treatment of diseases by inhibiting the autotaxin-LPA-LPAR pathway, offering potential therapeutic benefits for fibrotic, proliferative, inflammatory, autoimmune, respiratory, cardiovascular, and metabolic conditions.

JP2024543167AActive Publication Date: 2024-11-19SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024531402
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-17
Filing Date
2022-11-25
Publication Date
2024-11-19
Estimated Expiration
2042-11-25

AI Technical Summary

Technical Problem

There is an urgent need for small molecule inhibitors with novel structures that can effectively inhibit the enzymatic activity of autotaxin to alleviate or treat diseases associated with the autotaxin-LPA-LPAR signaling pathway, including fibrotic, proliferative, inflammatory, autoimmune, respiratory, cardiovascular, neurological, and metabolic diseases.

Method used

Development of tricyclic derivatives represented by specific formulas (I, II, and III) and their pharmaceutically acceptable salts, which act as autotaxin inhibitors by targeting the autotaxin-LPA-LPAR axis.

Benefits of technology

The tricyclic derivatives effectively inhibit autotaxin activity, potentially alleviating or treating a wide range of diseases by downregulating the LPA-LPAR signaling pathway, including fibrosis, tumors, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, and metabolic disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543167000001_ABST
    Figure 2024543167000001_ABST
Patent Text Reader

Abstract

Disclosed are tricyclic derivatives and their preparation and use, specifically, a compound represented by formula (I), its optical isomers or pharma- ceutically acceptable salts, and the use of said compounds as autotaxin inhibitors. [Formula 1] TIFF2024543167000287.tif63170
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] This application claims priority to: CN202111416045.3, the filing date is November 25, 2021; CN202211205107.0, the filing date is September 29, 2022; CN202211457401.0, application date is November 17, 2022.

[0002] [Technical field] The present invention relates to compounds of formula (I), their optical isomers and pharma- ceutically acceptable salts, and the use of said compounds as autotaxin inhibitors.

[0003] [Background technology] The present invention is a small molecule inhibitor of autotaxin (ATX). Autotaxin is also called ENPP2 (ectonucleotide pyrophosphatase / phosphodiesterase 2) and has two enzyme activities, phosphodiesterase (PDE) and lysophospholipase D (LysoPLD), and can catalyze the production of lysophosphatidic acid (LPA) using lysophosphatidylcholine (LPC) as a substrate. LPA binds to the G protein-coupled receptor LPAR A, which binds to the G protein-coupled receptor LPAR B, on the cell surface. 1-6Autotaxin is a signaling molecule that mediates various signaling pathways to cause a wide range of biological effects, regulates cell proliferation, survival and migration, and is involved in various physiological and pathological processes. Autotaxin is widely expressed in the human body, with the highest mRNA levels in the brain, lymph nodes, kidneys and testes, and is a key enzyme in the production of LPA in plasma and tissues. Autotaxin is localized to the cell surface by binding to cell surface molecules such as integrins, allowing LPA to be produced near the LPAR receptors and rapidly activate downstream signaling pathways. The specific biological activity of the autotaxin-LPA-LPAR axis is influenced by factors such as cell type, type and expression level of receptor subtypes, and LPC / LPA concentration, and has a wide range of physiological effects and cellular impacts.

[0004] There is evidence that the Autotaxin-LPA-LPAR axis is associated with a variety of diseases, including fibrotic diseases (e.g., pulmonary fibrosis, renal fibrosis, hepatic fibrosis, nonalcoholic steatohepatitis (NASH)), proliferative diseases (e.g., tumors), inflammatory diseases (e.g., enteritis, inflammatory pain), autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis), respiratory diseases (e.g., interstitial lung disease, asthma, chronic obstructive pulmonary disease (COPD)), cardiovascular diseases (e.g., vascular injury, atherosclerosis, blood clotting), neuropathic pain, myelodysplastic syndromes, obesity and metabolic diseases, as well as diseases associated with abnormal angiogenesis. Plasma LPA levels in heterozygous Autotaxin knockout mutant mice are approximately half that of normal mice, indicating that Autotaxin is the main source of LPA production. Therefore, if the enzymatic activity of Autotaxin can be effectively inhibited, it may be possible to alleviate or treat the associated diseases by downregulating the disease-related LPA-LPAR signaling pathway. Therefore, there is an urgent need in this technical field to develop small molecule inhibitors with novel structures, good druggability, and effective inhibition of Autotaxin enzymatic activity.

[0005] [Summary of the invention] In one aspect, the present invention provides a compound represented by formula (I), an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.

[0006] [ka]

[0007] however, Ring A is selected from cycloalkyl, heterocyclyl, and heteroaryl; Ring B is selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl; Ring C is selected from aryl and heteroaryl; Ring D is selected from aryl, heteroaryl, cycloalkyl, and heterocyclyl; X1 is C(R 7a ) and N; X2 is C(R 7b ) and N; X3 is C(R 7c ) and N; X4 is C(R 7d ) and N; L1 is a single bond, NR8, O, S and C 1-6 alkyl, R1 is independently selected from H, halogen, alkyl, haloalkyl, alkoxy, OH, hydroxyalkyl, cyano, amino, nitro, carboxy, aldehyde, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R2 is independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxy, aldehyde, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R3 is selected from H, alkyl, cycloalkyl, and heterocyclyl, each of which is optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, carboxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R4 is selected from H, halogen, alkyl, haloalkyl, heteroalkyl, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, -COOR9, aryl and heteroaryl, wherein said alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R5 are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxy, aldehyde, OH, hydroxyalkyl, oxo, cycloalkyl, heterocyclyl, aryl, and heteroaryl, each of which is optionally substituted by one or more substituents independently selected from halogen, alkyl, alkoxy, cyano, amino, nitro, carboxy, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R6 is -M-L2-R a and M is selected from a single bond or an alkyl, said alkyl being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, carboxy, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; L2 is a single bond, -C(=O)-, -C(=O)O-, -C(=O)NR b -, -NR b C(=O)-, -NRb C(=O)O-, -O-, -OC(=O)-, -C(=O)-C(=O)-, -C(=O)-C(=O)NR b -, -NR b -, -S(=O)2-, -S(=O)2NR b - and -NR b S(=O)2-, R a is H, -S(O)2R c , alkyl, -NR b R c , cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, oxo, cyano, amino, nitro, carboxy, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R b is selected from H, OH, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl; R c is selected from H and alkyl; R 7a , R 7b , R 7c , R 7d are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R8 is selected from H, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl; R9 is selected from H, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl; n is 0, 1, 2, 3 or 4; y is 0, 1, 2 or 3; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3.

[0008] In another aspect, the present invention further provides a compound represented by formula (II), an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.

[0009] [ka]

[0010] however, q is 0, 1, 2 or 3; X5 is O, S, N(R 4a ), C(R 4a )2 and C=O; X6 is O, S, N(R 4b ), C(R 4b )2 and C=O; X7 is independent of N(R 4c ), C(R 4c )2 and C=O;

[0011] [ka] represents a double bond or a single bond,

[0012] And between X5 and X6

[0013] [ka] represents a double bond, X5 is N and C(R 4a ), X6 is selected from N and C(R 4b ),

[0014] And X6 is not simultaneously linked to two double bonds; R 4a , R 4b , R 4c each independently represents H, halogen, alkyl, haloalkyl, heteroalkyl, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, -COOR 9, aryl and heteroaryl, wherein said alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; Ring B, ring C, ring D, R1, R2, R3, R5, R6, X1, X2, X3, X4, n, m, and y are as defined above.

[0015] In some embodiments of the present invention, the compound represented by the above formula (II), its optical isomer, or a pharma- ceutically acceptable salt thereof is

[0016] [ka] where each variable is as described above.

[0017] In some embodiments of the present invention, the compound represented by the above formula (II), its optical isomer, or a pharma- ceutically acceptable salt thereof is

[0018] [ka] where X5 is O, S, N(R 4a ), C(R 4a )2 and C=O, and X6 is selected from O, S, N(R 4b ), C(R 4b )2 and C=O, and each X7 is independently selected from N(R 4c ), C(R 4c )2 and C=O, the remainder of the variables being as defined herein.

[0019] In some embodiments of the present invention, the compound represented by the above formula (II), its optical isomer, or a pharma- ceutically acceptable salt thereof is

[0020] [ka] where X5 is selected from N and C(R 4a ), X6 is selected from N and C(R 4b ), and each X7 is independently selected from N(R 4c ), C(R 4c )2 and C=O, the remainder of the variables being as defined herein.

[0021] In some embodiments of the present invention, the compound represented by the above formula (II), its optical isomer, or a pharma- ceutically acceptable salt thereof is

[0022] [ka] It should be noted that when q is selected from 2 in formula (II-3), the structure of formula (II-3) is

[0023] [ka] and q is selected from 3, the structure of formula (II-3) is

[0024] [ka] where X5 is O, S, N(R 4a ), C(R 4a )2 and C=O, and X6 is selected from N and C(R 4b ), and when the bond connected to X7 is a double bond, each X7 is independently selected from N and C(R 4b ), and when the bond connected to X7 is a single bond, each X7 is independently selected from N(R 4c ), C(R 4c )2 and C=O, the remainder of the variables being as defined herein.

[0025] In another aspect, the present invention further provides a compound represented by formula (III), an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.

[0026] [ka]

[0027] however, X8 is independent of O, S, N(R 2a ), -N=CH-, -CH=N- and -CH=CH; X9 are each independently 2b ) and N; R 2a , R 2b are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxy, aldehyde, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; Ring B, ring D, R1, R3, R5, R6, X1, X2, X3, X4, n, and m are as defined above; X5, X6, X7, q,

[0028] [ka] is as defined above.

[0029] In some embodiments of the present invention, the compound represented by the above formula (III), its optical isomer, or a pharma- ceutically acceptable salt thereof is

[0030] [ka] where each variable is as described above.

[0031] In some embodiments of the present invention, the compound represented by the above formula (III), its optical The isomer or a pharma- ceutically acceptable salt thereof is

[0032] [ka] where X5 is O, S, N(R 4a ), C(R 4a )2 and C=O, and X6 is selected from O, S, N(R 4b ), C(R 4b )2 and C=O, and each X7 is independently selected from N(R 4c ), C(R 4c )2 and C=O, the remainder of the variables being as defined herein.

[0033] In some embodiments of the present invention, the compound represented by the above formula (III), its optical isomer, or a pharma- ceutically acceptable salt thereof is

[0034] [ka] where X5 is selected from N and C(R 4a ), X6 is selected from N and C(R 4b ), and each X7 is independently selected from N(R 4c ), C(R 4c )2 and C=O, the remainder of the variables being as defined herein.

[0035] In some embodiments of the present invention, the compound represented by the above formula (III), its optical isomer, or a pharma- ceutically acceptable salt thereof is

[0036] [ka] It should be noted that when q is selected from 2 in the formula (III-3), the structure of the formula (III-3) is

[0037] [ka] and when q is selected from 3, the structure of formula (III-3) is

[0038] [ka] where X5 is O, S, N(R 4a ), C(R 4a )2 and C=O, and X6 is selected from N and C(R 4b ), and when the bond connected to X7 is a double bond, each X7 is independently selected from N and C(R 4b ), and when the bond connected to X7 is a single bond, each X7 is independently selected from N(R 4c ), C(R 4c )2 and C=O, the remainder of the variables being as defined herein.

[0039] In some embodiments of the present invention, ring A is C 4-8 Cycloalkyl, 4-8 membered is selected from heterocyclyl and 5-6 membered heteroaryl, the remaining variables being as defined herein.

[0040] In some embodiments of the present invention, ring A is C 4-6 is selected from cycloalkyl, 5- to 6-membered heterocyclyl, and 5- to 6-membered heteroaryl, the remaining variables being as defined herein.

[0041] In some embodiments of the present invention, Ring A above is selected from cyclobutyl, cyclopentyl, tetrahydrofuranyl, pyrrolidinyl, cyclopentanone, dihydrofuran-2(3H)-one, pyrrolidin-2-one, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, and 1,2,3-oxadiazolyl, and the remaining variables are as defined herein.

[0042] In some embodiments of the present invention, each R4 is independently H, OH, C 1-6 Alkyl and C 1-6 heteroalkyl, 1-6 Alkyl and C 1-6The heteroalkyl is optionally substituted with one or more of OH, amino, halogen, and the remaining variables are as defined herein.

[0043] In some embodiments of the present invention, each R4 is independently H, OH, C 1-6 Alkyl and C 1-6 alkyl-C(=O)O-, 1-6 Alkyl and C 1-6 The alkyl -C(=O)O- is optionally substituted with one or more of OH, amino, halogen, and the remaining variables are as defined herein.

[0044] In some embodiments of the present invention, each R4 is independently H, OH, methyl, ethyl,

[0045] [ka] , CF3, with the remainder of the variables being as defined herein.

[0046] In some embodiments of the present invention, the above R 4a , R 4b , R 4c are independently H, OH, and C 1-6 Alkyl and C 1-6 heteroalkyl, 1-6 Alkyl and C 1-6 The heteroalkyl is optionally substituted with one or more of OH, amino, halogen, and the remaining variables are as defined herein.

[0047] In some embodiments of the present invention, the above R 4a , R 4b , R 4c are independently H, OH, and C 1-6 Alkyl and C 1-6 alkyl-C(=O)O-, 1-6 Alkyl and C 1-6The alkyl -C(=O)O- is optionally substituted with one or more of OH, amino, halogen, and the remaining variables are as defined herein.

[0048] In some embodiments of the present invention, the above R 4a , R 4b , R 4c are each independently H, OH, methyl, ethyl,

[0049] [ka] , CF3, with the remainder of the variables being as defined herein.

[0050] In some embodiments of the present invention, the above structural unit

[0051] [ka] teeth,

[0052] [ka] and the remaining variables are as defined herein.

[0053] In some embodiments of the present invention, ring B is phenyl, 5- to 6-membered heteroaryl, C 3-6 is selected from cycloalkyl, 5- to 6-membered heterocyclyl, benzo 5- to 6-membered heterocyclyl, and 5- to 9-membered bicycloalkyl, the remaining variables being as defined herein.

[0054] In some embodiments of the present invention, ring B is phenyl, pyridyl, C 3-6 is selected from cycloalkyl, 5- to 6-membered heterocycloalkyl, benzo 5- to 6-membered heterocycloalkyl, and 5- to 9-membered bicycloalkyl, the remaining variables being as defined herein.

[0055] In some embodiments of the present invention, Ring B is selected from phenyl, pyridyl, cyclohexyl, tetrahydro-2H-pyranyl, benzo[d][1,3]dioxazolyl, and bicyclo[1.1.1]pentyl, and the remaining variables are as defined herein.

[0056] In some embodiments of the present invention, the above structural unit

[0057] [ka] teeth,

[0058] [ka] and the remaining variables are as defined herein.

[0059] In some embodiments of the present invention, ring D is phenyl, 5-6 membered heteroaryl, C 3-6 is selected from cycloalkyl and 6- to 10-membered heterocyclyl, the remainder of the variables being as defined herein.

[0060] In some embodiments of the present invention, Ring D is selected from piperazinyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[4.4]nonyl, 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[3.5]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, and octahydropyrrolo[3,4-c]pyrrolyl, and the remaining variables are as defined herein.

[0061] In some embodiments of the present invention, ring D above is

[0062] [ka] and the remaining variables are as defined herein.

[0063] In some embodiments of the present invention, the above R a -H,C 1-6 is selected from alkyl, NHOH, -N(CH3)2, -NHCH3, 4- to 9-membered heterocyclyl, and 4- to 9-membered cycloalkyl, wherein said 4- to 9-membered heterocyclyl or 4- to 9-membered cycloalkyl is optionally substituted by one, two or three of OH, methyl, ethyl, or halogen, and the remaining variables are as defined herein.

[0064] In some embodiments of the present invention, R6 above is -C 1-3 Alkyl-C(=O)-3 to 9-membered heterocyclyl, -C 1-3 Alkyl-C(=O)-3 to 9-membered heterocyclyl-C 1-6 Alkyl, -C(=O)-3 to 9 membered heterocyclyl, -C(=O)-C 3-9 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C 1-3 Alkyl-C(=O)-NH-C 1-6 Alkyl, -S(=O)2-C 1-3 Alkyl and -C 1-3 alkyl-C(=O)NH-OH, 1-3 Alkyl-C(=O)-3 to 9-membered heterocyclyl, -C 1-3 Alkyl-C(=O)-3 to 9-membered heterocyclyl-C 1-6 Alkyl, -C(=O)-5 to 6-membered heterocyclyl, -C(=O)-C 3-9 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C 1-3 Alkyl-C(=O)-NH-C 1-6 Alkyl, -S(=O)2-C 1-3 Alkyl or -C 1-3 The alkyl-C(=O)NH-OH is optionally substituted with one, two or three of OH, amino, methyl, ethyl, hydroxymethyl, trifluoromethyl, methoxy or halogen, and the remaining variables are as defined herein.

[0065] In some embodiments of the present invention, R6 above is

[0066] [ka] and

[0067] [ka] is optionally substituted with one, two or three of OH, methyl, ethyl, hydroxymethyl or halogen, and the remaining variables are as defined herein.

[0068] In some embodiments of the present invention, R6 above is

[0069] [ka] and the remaining variables are as defined herein.

[0070] In some embodiments of the present invention, the above structural unit

[0071] [ka] teeth,

[0072] [ka] TIFF2024543167000032.tif28170, and the remaining variables are as defined in the present invention.

[0073] In some embodiments of the present invention, R3 above is H, C 1-6 Alkyl, C 3-6 S chloroalkyl and 4- to 6-membered heterocyclyl, 1-6 Alkyl, C 3-6 Cycloalkyl or 4-6 membered heterocyclyl is halogen, cyano, amino, C 1-6 It is optionally substituted with one, two or three alkyl groups, the remaining variables being as defined herein.

[0074] In some embodiments of the present invention, R3 above is H, methyl, ethyl,

[0075] [ka] and the remaining variables are as defined herein.

[0076] In some embodiments of the present invention, the ring C is selected from a 5-6 membered heteroaryl, the heteroaryl containing 1-3 heteroatoms selected from N, O or S atoms, and the remaining variables are as defined herein.

[0077] In some embodiments of the present invention, the above R 7a , R 7b , R 7c , R 7d are each independently H, halogen, or C 1-6 Alkyl, C 1-6 Alkoxy, cyano, amino, nitro, OH, C 3-6 cycloalkyl, 5- to 6-membered heterocyclyl, phenyl, and 5- to 6-membered heteroaryl, 1-6 The alkyl is optionally substituted with 1, 2 or 3 halogens, and the remaining variables are as defined herein.

[0078] In some embodiments of the present invention, the above structural unit

[0079] [ka] teeth,

[0080] [ka] and the remaining variables are as defined herein.

[0081] In some embodiments of the present invention, the above structural unit

[0082] [ka] teeth,

[0083] [ka] and the remaining variables are as defined herein.

[0084] In another aspect of the present invention, the present invention further provides a compound of the following formula, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from the following formulae:

[0085] [ka] TIFF2024543167000039.tif238170TIFF2024543167000040.tif241170TIFF2024543167 000041.tif238170TIFF2024543167000042.tif221170TIFF2024543167000043.tif24017 0TIFF2024543167000044.tif220170TIFF2024543167000045.tif223170TIFF2024543167 000046.tif237170TIFF2024543167000047.tif210170TIFF2024543167000048.tif74170

[0086] Another aspect of the present invention further provides a compound of the following formula, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from the formulae:

[0087] [ka]

[0088] In another aspect of the present invention, the present invention further provides the use of the above compound, its optical isomer or its pharma- ceutically acceptable salt in the preparation of a medicament for treating an ATX-associated disease.

[0089] In some embodiments of the invention, the ATX-associated disease is selected from cancer, metabolic disease, kidney disease, liver disease, fibrotic disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative disease, myelodysplastic syndrome, obesity, skin disease, and / or disease associated with abnormal angiogenesis.

[0090] In some embodiments of the invention, the fibrotic disease is selected from pulmonary fibrosis, renal fibrosis, hepatic fibrosis, and the like. In some embodiments of the invention, the pulmonary fibrosis is selected from idiopathic pulmonary fibrosis, non-idiopathic pulmonary fibrosis, and the like.

[0091] In some embodiments of the invention, the liver disease is selected from non-alcoholic steatohepatitis and the like. In some embodiments of the invention, the inflammatory disease is selected from enteritis, osteoarthritis, and the like.

[0092] In some embodiments of the invention, the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, and the like. In some embodiments of the invention, the respiratory disease is selected from interstitial lung disease, asthma, COPD, and the like.

[0093] In some embodiments of the invention, the cardiovascular disease is selected from vascular injury, atherosclerosis, blood clotting, and the like. Definitions and Explanations Unless otherwise stated, the following terms and phrases used herein have the following meanings: Certain terms and phrases, unless specifically defined, should not be considered indefinite or unclear, but should be understood according to their ordinary meaning. When trade names appear herein, it is intended to refer to the corresponding product or its active ingredients.

[0094] As used herein, the term "pharmacologically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals and are commensurate with a reasonable benefit / risk ratio without undue toxicity, irritation, allergic response or other problem or complication.

[0095] The term "pharmaceutical acceptable salt" refers to a salt of a compound of the present invention, which is prepared with a relatively non-toxic acid or base with a compound having a specific substituent discovered in this invention. When the compounds of the present invention contain a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of these compounds with a sufficient amount of base in a single solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts, or similar salts. When the compounds of the present invention contain a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of these compounds with a sufficient amount of acid in a single solution or in a suitable inert solvent. Pharmaceutically acceptable acid addition salts include inorganic acid salts including hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, and phosphorous acid; organic acid salts including acetic acid, propionic acid, isobutyric acid, trifluoroacetic acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid and similar acids; salts of amino acids (e.g., arginine, etc.), and salts of organic acids such as glucuronic acid. Some specific compounds of the present invention contain basic and acidic functional groups and can be converted into any base or acid addition salt.

[0096] The pharma- ceutically acceptable salts of the present invention can be synthesized in a conventional manner from the parent compound which contains an acidic or basic group. Typically, such salts are prepared by reacting the compound in its free acid or base form with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or a mixture of both.

[0097] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, and all such mixtures are included within the scope of the present invention. Other asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers and mixtures thereof are all included within the scope of the present invention.

[0098] The compounds of the present invention may exist in specific forms. Unless otherwise stated, the term "tautomer" or "tautomeric form" refers to isomers of different functional groups that are in dynamic equilibrium at room temperature and can be rapidly converted between each other. Tautomers can reach chemical equilibrium of tautomers when possible (e.g., in solution). For example, proton tautomers (also called prototropic tautomers) include interconversions via the transfer of protons, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by rearrangement of some bond electrons. Among them, a specific example of keto-enol tautomerization is the interconversion between the two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.

[0099] The compounds of the present invention may contain unnatural atomic isotopes at one or more atoms that constitute the compounds. For example, tritium ( 3 H), iodine-125(125 I) or C-14( 14 Compounds can be labeled with radioisotopes such as C). For example, deuterium can be replaced with hydrogen to form a deuterated drug, where the bond formed between deuterium and carbon is stronger than the bond formed between normal hydrogen and carbon, and compared to non-deuterated drugs, deuterated drugs have the advantages of reduced toxic side effects, increased drug stability, improved therapeutic efficacy, and increased biological half-life. All isotopic variations of the compounds of the invention, whether radioactive or not, are within the scope of the invention. "Optional" or "optionally" means that a subsequent event or circumstance may occur, but does not necessarily occur, and the description includes cases where the event or circumstance occurs and cases where the event or circumstance does not occur.

[0100] The term "substituted by" means that any one or more H at a particular atom is replaced by a substituent, and may include variants of deuterium and hydrogen, so long as the valence of the particular atom is normal and the compound after substitution is stable. The term "optionally substituted by" refers to substitution or no substitution, and unless otherwise stated, the type and number of substituents may be any, as long as they are chemically feasible.

[0101] When any variable (e.g., R) occurs more than one time in a composition or structure of a compound, its definition is independent at each occurrence. Thus, for example, if a group is substituted with 0-2 R, then said group may be optionally substituted with up to 2 R, and each occurrence of R has independent options. Furthermore, combinations of substituents and / or variants thereof are permissible only if such combinations result in stable compounds. For example,

[0102] [ka] teeth,

[0103] [ka] and the like.

[0104] A dash ("-") that is not between two letters or symbols indicates the point of attachment of a substituent. For example, C 1-6 Alkylcarbonyl- is attached to the rest of the molecule through a carbonyl. 1-6 refers to alkyl, except where the point of attachment of the substituent is clear to one of ordinary skill in the art, such as a halogen substituent, the "-" may be omitted.

[0105] When one of the variables is a single bond, it represents that the two groups connected thereto are directly linked, for example:

[0106] [ka] When L1 in the formula represents a single bond, the structure is actually

[0107] [ka] Represents.

[0108] Unless otherwise stated,

[0109] [ka] ", the valence bond of the group is marked with a dotted line "

[0110] [ka] ", a dotted line indicates the point of attachment of the group to the rest of the molecule.

[0111] If a given substituent does not specify through which atom it is attached to the substituted group, then such substituent may be attached through any atom thereof; for example, a pyridyl group as a substituent may be attached to the substituent through any carbon atom of the pyridine ring. good.

[0112] When the direction of the linkage is not specified for a given linking group, the linkage may be in any direction, for example:

[0113] [ka] The linking group L in

[0114] [ka] At this time

[0115] [ka] is a phenyl and cyclopentyl bond in the same direction as the left-to-right reading order.

[0116] [ka] The phenyl and cyclopentyl may be linked in the opposite direction to the left-to-right reading order.

[0117] [ka] Combinations of the above linking groups, substituents and / or variables thereof are permissible only if such combinations result in stable compounds.

[0118] Unless otherwise defined, the number of atoms in a ring is usually defined as the number of members in the ring, for example, a "4- to 6-membered ring" refers to a "ring" having 4 to 6 atoms arranged in a ring. Unless otherwise defined, the term "alkyl" refers to a straight or branched chain saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, which may be monovalent (e.g., methyl), divalent (e.g., methylene) or polyvalent (e.g., methine). Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2 ,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3 ,3-diethylhexyl, 2,2-diethylhexyl, methylene (-CH2-), 1,1-ethylidene (-CH(CH3)-), 1,2-ethylidene (-CH2CH2-), 1,1-propylidene (-CH(CH2CH3)-), 1,2-propylidene (-CH2CH(CH3)-), 1,3-propylidene (-CH2CH2CH2-), 1,4-butylidene (-CH2CH2CH2CH2-) and various branched chain isomers thereof. More preferably, it is a lower alkyl containing from 1 to 6 carbon atoms, non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl may be substituted or unsubstituted, and when substituted, the substituents may be substituted at any available point of attachment, and said substituents are preferably one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, OH, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo.

[0119] The term "heteroalkyl," by itself or in combination with other terms, refers to a stable linear or branched alkyl radical or combination thereof consisting of the specified number of carbon atoms and at least one heteroatom or heteroatom group. In some embodiments, the heteroatom is selected from B, O, N, and S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen heteroatom is optionally quaternized. In other embodiments, the heteroatom group is selected from -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O), -S(=O)2-, -C(=O)N(H)-, -N(H)-, -C(=NH)-, -S(=O)2N(H)-, and -S(=O)N(H)-. In some embodiments, the heteroalkyl is selected from C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)-, -C(=O)N(H)-, -C(=NH)-, -S(=O)N(H)-, and -S(=O)N(H)-. 1-6 In another embodiment, the heteroalkyl is C 1-3 Although the heteroatom or heteroatom group may be placed at any interior position of the heteroalkyl, including the position at which the alkyl is attached to the remainder of the molecule, the term "alkoxy" is a convention and refers to an alkyl group attached to the remainder of the molecule via an oxygen atom. Examples of heteroalkyl include, but are not limited to, -OCH, -OCHCH, -OCHCHCH, -OCH(CH), -CH-CH-O-CH, -NHCH, -N(CH), -NHCHCH, -N(CH)(CHCH), -CH-CH-NH-CH, -CH-CH-N(CH)-CH, -SCH, -SCHCH, -SCHCHCH, -SCH(CH), -CH-S-CH-CH, -CH-CH, -S(=O)-CH, -CH-CH-S(=O)-CH, and up to two heteroatoms may be consecutive, e.g., -CH-NH-OCH.

[0120] Unless otherwise defined, "C 1-6 The term "alkoxy" refers to an alkyl group containing 1 to 6 carbon atoms attached to the remainder of the molecule through an oxygen atom. 1-6 Alkoxy is C 1-4 , C 1-3 , C 1-2 , C2-6 , C 2-4 , C6, C5, C4 and C3 alkoxy, etc. 1-6 Examples of alkoxy are methoxy, ethoxy, and propyl. These include, but are not limited to, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentyloxy (including n-pentyloxy, isopentyloxy and neopentyloxy), hexyloxy and the like.

[0121] Unless otherwise defined, "C 1-3 The term "alkoxy" refers to an alkyl group containing 1 to 3 carbon atoms attached to the remainder of the molecule through an oxygen atom. 1-3 Alkoxy is C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkoxy, etc. 1-3 Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

[0122] Unless otherwise defined, "C 1-6 The term "alkylamino" refers to an alkyl group containing 1 to 6 carbon atoms attached to the remainder of the molecule through an amino. 1-6 Alkylamino is C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylamino, etc. 1-6 Examples of alkylamino include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -N(CH2CH3)(CH2CH3), -NHCH2CH2CH3, -NHCH2(CH3)2, -NHCH2CH2CH2CH3, and the like.

[0123] Unless otherwise defined, "C 1-3The term "alkylamino" refers to an alkyl group containing 1 to 3 carbon atoms attached to the remainder of the molecule through an amino group. 1-3 Alkylamino is C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylamino, etc. 1-3 Examples of alkylamino include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, and the like.

[0124] Unless otherwise defined, "C 1-6 The term "alkylthio" refers to an alkyl group containing 1 to 6 carbon atoms attached to the remainder of the molecule through a sulfur atom. 1-6 Alkylthio is C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylthio. 1-6 Examples of alkylthio include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH2(CH3)2, and the like.

[0125] Unless otherwise defined, "C 1-3 The term "alkylthio" refers to an alkyl group containing 1 to 3 carbon atoms attached to the remainder of the molecule through a sulfur atom. 1-3 Alkylthio is C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylthio, etc. 1-3 Examples of alkylthio include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH2(CH3)2, and the like.

[0126] Unless otherwise defined, the term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms (either at the specified end points or between any two end points, e.g., 3, 4, 5, 6 ring atoms, 4 to 11 ring atoms, 6 to 12 ring atoms, etc.), more preferably 3 to 8 carbon atoms, and most preferably 3 to 6 (e.g., 3, 4, 5, or 6) carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc., preferably cycloalkyl, and polycyclic cycloalkyls include spirocycloalkyls, fused cycloalkyls, and bridged cycloalkyls.

[0127] Unless otherwise defined, the term "spirocycloalkyl" refers to a 5-20 membered polycyclic group sharing one carbon atom (called a spiro atom) between the rings, which may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. Preferably, it is 6-14 membered, more preferably 7-10 membered. According to the number of spiro atoms shared between the rings, spirocycloalkyls can be classified into monocyclic spirocycloalkyls, bicyclic spirocycloalkyls or polycyclic spirocycloalkyls, preferably monocyclic spirocycloalkyls and bicyclic spirocycloalkyls. More preferably, it is 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monocyclic spirocycloalkyls. Non-limiting examples of spirocycloalkyls are:

[0128] [ka] etc.

[0129] Unless otherwise defined, the term "fused cycloalkyl" refers to a 5-20 member all-carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with the other rings in the system, and one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. Preferably, it is 6-14 membered, more preferably 7-10 membered. According to the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic cycloalkyl. Non-limiting examples of fused cycloalkyl are:

[0130] [ka] etc.

[0131] Unless otherwise defined, the term "bridged cycloalkyl" refers to a 5-20 member all-carbon polycyclic group having any two rings sharing two carbon atoms that are not directly bonded, which may contain one or more double bonds, but neither ring has a completely conjugated π-electron system. It is preferably 6-14 membered, more preferably 7-10 membered. According to the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl are:

[0132] [ka] etc.

[0133] The cycloalkyl includes the above cycloalkyls fused to an aryl, heteroaryl, or heterocycloalkyl ring (e.g., monocyclic cycloalkyls, fused cycloalkyls, spirocycloalkyls, and bridged cycloalkyls), where the ring attached to the parent structure is a cycloalkyl; non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, and the like, preferably benzocyclopentyl, tetrahydronaphthyl.

[0134] Cycloalkyl can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, OH, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo.

[0135] Unless otherwise defined, the term "heterocyclyl" refers to a heterocyclic ring containing 3 to 20 ring atoms, one or more of which is nitrogen, oxygen, or S(O). m (m is an integer of 0 to 2), but does not include the ring moiety of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms (which may be a specific point or the interval between any two end points, for example, 3, 4, 5, 6 ring atoms, 4 to 11 ring atoms, 6 to 12 ring atoms, etc.), of which 1 to 4 are heteroatoms, preferably contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms, and more preferably contains 3 to 6 ring atoms, of which 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclyls include azetidinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like, preferably tetrahydropyranyl, piperidinyl, pyrrolidinyl. Polycyclic heterocyclyls include spiroheterocyclyl, fused heterocyclyl, and bridged heterocyclyl.

[0136] Unless otherwise defined, the term "spiroheterocyclyl" refers to a 5-20 membered polycyclic heterocyclic group that shares one atom (called a spiro atom) between the monocyclic rings, in which one or more of the ring atoms is nitrogen, oxygen, or S(O) m (m is an integer from 0 to 2), and the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. It is preferably 6 to 14-membered, more preferably 7 to 11-membered. According to the number of spiro atoms shared between the rings, spiroheterocyclyls can be classified into monocyclic spiroheterocyclyls, bicyclic spiroheterocyclyls or polycyclic spiroheterocyclyls, preferably monocyclic spiroheterocyclyls and bicyclic spiroheterocyclyls. More preferably, it is 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monocyclic spiroheterocyclyls. Non-limiting examples of spiroheterocyclyls are:

[0137] [ka] etc.

[0138] Unless otherwise defined, the term "fused heterocyclyl" refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with another ring in the system, one or more of the rings may contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, and one or more of the ring atoms is nitrogen, oxygen, or S(O) m (m is an integer of 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14-membered, more preferably 7 to 11-membered. According to the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclyl, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclyl. Non-limiting examples of fused heterocyclyl are:

[0139] [ka] etc.

[0140] Unless otherwise defined, the term "bridged heterocyclyl" refers to a 5-14 membered polycyclic heterocyclic group having two rings sharing any two atoms that are not directly bonded, which may contain one or more double bonds, but neither ring has a completely conjugated pi-electron system, and one or more of the ring atoms is nitrogen, oxygen, or S(O). m (m is an integer of 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14-membered, more preferably 7 to 11-membered. According to the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclyl, and is preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclyl are:

[0141] [ka] etc.

[0142] The heterocyclyl rings include the above heterocyclyls fused to an aryl, heteroaryl, or cycloalkyl ring (e.g., monocyclic heterocyclyls, fused heterocyclyls, spiroheterocyclyls, and bridged heterocyclyls), where the ring attached to the parent structure is a heterocyclyl, non-limiting examples of which are:

[0143] [ka] etc.

[0144] The heterocyclyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, OH, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo.

[0145] Unless otherwise defined, the term "aryl" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated pi-electron system having 6 to 20 members, preferably 6 to 10 members, more preferably 6 members, such as phenyl and naphthyl. The aryl ring includes the above aryls fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, where the ring attached to the parent structure is an aryl ring, non-limiting examples of which are:

[0146] [ka] etc.

[0147] Aryl may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, OH, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0148] Unless otherwise defined, the term "heteroaryl" refers to a heteroaromatic system containing 1-4 heteroatoms and 5-20 ring atoms, where the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 5-10 membered and contains 1-3 heteroatoms, more preferably 5 or 6 membered and contains 1-3 heteroatoms, non-limiting examples include pyrazolyl, imidazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, thiadiazolyl, pyrazinyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, where the ring attached to the parent structure is a heteroaryl ring, non-limiting examples of which are:

[0149] [ka] etc.

[0150] Heteroaryl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, OH, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0151] Unless otherwise stated, the term "alkylthio" refers to -S-(alkyl) and -S-(unsubstituted cycloalkyl), where alkyl or cycloalkyl are defined above. Non-limiting examples of alkylthio include methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio. Alkylthio can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, OH, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0152] Unless otherwise defined, the term "amino-protecting group" is used to protect an amino group with a group that can be easily removed so that the amino group is not changed when other parts of the molecule react. Non-limiting examples include tert-butoxycarbonyl, acetyl, benzyl, allyl, p-methoxybenzyl, etc. These groups may be optionally substituted with 1 to 3 substituents selected from halogen, alkoxy, or nitro. The amino protecting group is preferably tert-butoxycarbonyl.

[0153] Unless otherwise defined, the term "cycloalkoxy" refers to --O-cycloalkyl, where cycloalkyl is as defined above. Unless otherwise defined, the term "haloalkyl" refers to an alkyl substituted with a halogen, where alkyl is as defined above.

[0154] Unless otherwise defined, the term "haloalkoxy" refers to an alkoxy substituted with a halogen, where alkoxy is as defined above. Unless otherwise defined, the term "hydroxyalkyl" refers to an alkyl substituted with OH, where alkyl is as defined above.

[0155] Unless otherwise defined, the term "hydroxy" refers to an --OH group. Unless otherwise defined, the term "halogen" refers to fluorine, chlorine, bromine, and iodine. Unless otherwise defined, the term "aldehyde" refers to -C(O)H.

[0156] Unless otherwise defined, the term "carboxy" refers to -C(O)OH. Unless otherwise defined, the term "carboxylate group" refers to a -C(O)O(alkyl) or -C(O)O(cycloalkyl), where alkyl, cycloalkyl are defined above.

[0157] Unless otherwise defined, the term "C 1-6 "Alkyl" refers to a linear or branched saturated hydrocarbon group consisting of 1 to 6 carbon atoms. 1-6 Alkyl is C 1-5 , C 1-4 , C 2-6 alkyl, which may be monovalent (e.g., methyl), divalent (e.g., methylene) and polyvalent (e.g., methine). 1-5 Illustrative examples of alkyl include, but are not limited to, methyl ("Me"), ethyl ("Et"), propyl, such as, for example, n-propyl ("n-Pr") or isopropyl ("i-Pr"), butyl, such as, for example, n-butyl ("n-Bu"), isobutyl ("i-Bu"), s-butyl ("s-Bu") or t-butyl ("t-Bu"), pentyl, hexyl, and the like.

[0158] Unless otherwise defined, the term "C 1-3 "Alkyl" refers to a saturated hydrocarbon group consisting of 1 to 3 carbon atoms in a straight or branched chain. 1-3 Alkyl has C 1-2 and C. 2-3Alkyl, which may be monovalent (e.g., methyl), divalent (e.g., methylene) and polyvalent (e.g., methine). 1-3 Examples of alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl).

[0159] Unless otherwise defined, "C 2-6 "Alkenyl" refers to a straight or branched chain hydrocarbon group of 2 to 6 carbon atoms containing at least one carbon-carbon double bond, which may be located at any position in the group. 2-6 Alkenyl is C 2-4 , C 2-3 , C4, C3 and C2 alkenyl, which can be monovalent, divalent or polyvalent. 2-6 Examples of alkenyl include, but are not limited to, vinyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, and the like.

[0160] Unless otherwise defined, "C 2-3 "Alkenyl" refers to a straight or branched chain hydrocarbon group of 2 to 3 carbon atoms containing at least one carbon-carbon double bond, which may be located at any position in the group. 2-3 Alkenyl is C3 and C2 alkenyl. C includes ethylenyl, 2-3 Alkenyl can be monovalent, divalent or polyvalent. 2-3 Examples of alkenyl include, but are not limited to, vinyl, propenyl, and the like.

[0161] Unless otherwise defined, "C 4-8 "Cycloalkyl" refers to saturated monovalent monocyclic and bicyclic cyclic hydrocarbon radicals containing 4 to 8 carbon atoms, for example, 4 to 7 ring carbon atoms, for example, 4 to 6 ring carbon atoms, for example, 4 to 5 ring carbon atoms. 4-8 "Cycloalkyl" refers to a cycloalkyl containing 4 to 8 ring carbon atoms. 4-7"Cycloalkyl" refers to a cycloalkyl containing 4 to 7 ring carbon atoms. 4-6 "Cycloalkyl" refers to a cycloalkyl containing 4 to 6 ring carbon atoms. 4-5 "Cycloalkyl" refers to a cycloalkyl containing 4 to 5 ring carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.

[0162] Unless otherwise stated, "C 4-6 "Cycloalkyl" means a saturated cyclic hydrocarbon group of 4 to 6 carbon atoms, which may be monocyclic or bicyclic, and the C 4-6 Cycloalkyl has C 4-5 , C 5-6 , C4, C5 and C6 cycloalkyl, which may be monovalent, divalent or polyvalent. 4-6 Examples of cycloalkyl include, but are not limited to, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0163] Unless otherwise stated, the term "3- to 10-membered heterocyclyl", by itself or in combination with other terms, means a saturated cyclic group consisting of 3 to 10 ring atoms, respectively, in which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, in which the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., NO and S(O)). p, p is 1 or 2). It includes monocyclic and bicyclic ring systems, where bicyclic systems include spiro, fused and bridged rings. Additionally, for the "3- to 10-membered heterocycloalkyl", a heteroatom can occupy the position connecting the heterocycloalkyl to the remainder of the molecule. The 3- to 10-membered heterocyclyl includes 6- to 9-membered, 3- to 6-membered, 3- to 5-membered, 4- to 6-membered, 5- to 6-membered, 4-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, 10-membered heterocyclyl, etc. Illustrative examples of 3- to 10-membered heterocyclyl include azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl, and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl, etc.), and the like. Examples of 5- to 9-membered bicycloalkyl include, but are not limited to, 5- to 9-membered fused rings in a bicyclic ring system, such as, for example, bicyclo[1.1.1]pentyl, 2,5-diazabicyclo[2.2.1]heptyl, and the like.

[0164] Unless otherwise stated, the term "3- to 6-membered heterocyclyl", by itself or in combination with other terms, means a saturated cyclic group consisting of 3 to 6 ring atoms, respectively, in which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, in which the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., NO and S(O)). p , p is 1 or 2 It includes monocyclic and bicyclic ring systems, where bicyclic systems include spiro, fused and bridged rings. Additionally, for the "3- to 6-membered heterocyclyl", a heteroatom can occupy the position connecting the heterocycloalkyl to the remainder of the molecule. The 3- to 6-membered heterocycloalkyl includes 5- to 6-membered, 4-membered, 5-membered and 6-membered heterocycloalkyl, and the like. Illustrative examples of 4-6 membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl, and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxolyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl, or homopiperidinyl, etc.

[0165] Unless otherwise defined, C n-n+m Or C n ~C n+m includes any one of the specific cases of n to n+m carbons, for example, C 1-12 are C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 and C 12Including any range of n to n+m, for example, C 1-12 is C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 and C 9-12 By the same principle, n-membered to n+m-membered rings indicate that the number of atoms on the ring is n to n+m, and for example, a 3- to 12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, and a 12-membered ring, and also includes any range of n to n+m, and for example, a 3- to 12-membered ring includes a 3- to 6-membered ring, a 3- to 9-membered ring, a 5- to 6-membered ring, a 5- to 7-membered ring, a 6- to 7-membered ring, a 6- to 8-membered ring, and a 6- to 10-membered ring, etc.

[0166] "Optionally" or "optionally" means that the subsequently described event or circumstance may, but does not necessarily, occur, and the description includes situations where the event or circumstance occurs or where the event or circumstance does not occur. For example, "a heterocyclyl group optionally substituted with alkyl" means that alkyl may, but does not necessarily, be present, and the description includes situations where the heterocyclyl group is substituted with alkyl and situations where the heterocyclyl group is not substituted with alkyl.

[0167] "Substituted" means that one or more H, preferably up to 5, more preferably 1 to 3 H in the group, are each independently replaced by a corresponding number of substituents, where each substituent has an independent option (i.e., the substituents can be the same or different). Needless to say, the substituents are only present at possible chemical positions, and the skilled person can determine possible or impossible substitutions (experimentally or theoretically) without undue effort. For example, amino or OH containing free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (e.g., olefinic bond).

[0168] It should be understood by those skilled in the art that some compounds of formula (I) may contain one or more chiral centers and therefore may exist in two or more stereoisomers.Accordingly, the compounds of the present invention may exist in the form of single stereoisomers (e.g., enantiomers, diastereomers) and mixtures thereof in any ratio, e.g., in the form of racemates, and, if necessary, in the form of their tautomers and geometric isomers.

[0169] The term "stereoisomers" as used herein refers to compounds that have identical chemical structure, but differ in the arrangement of the atoms or groups in space. Stereoisomers include enantiomers, diastereomers, and conformational isomers.

[0170] The term "enantiomers" as used herein refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. The term "diastereomer" as used herein refers to a stereoisomer that has two or more chiral centers and whose molecules are not mirror images of one another. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, or biological activity. Mixtures of diastereomers can be separated using high resolution analytical methods such as electrophoresis and chromatography, such as HPLC.

[0171] For definitions and conventions of stereochemistry, see S.P. Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration about the chiral center of the molecule. The prefixes d and l, or (+) and (-), are symbols used to specify the rotation of plane-polarized light by a compound, where (-) or l indicates that the compound is levorotatory. Compounds prefixed with (+) or d are dextrorotatory. For a particular chemical structure, these stereoisomers are identical except that they are mirror images of each other. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate and may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that is devoid of optical activity.

[0172] Racemic mixtures can be used as is or resolved into individual isomers. Resolution can provide stereochemically pure compounds or mixtures enriched in one or more isomers. Methods for separating isomers are well known (see Allinger NL and Eliel EL, "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) and include physical methods such as chromatography using chiral adsorbents. Chiral forms of individual isomers can be prepared from chiral precursors. Alternatively, diastereomeric salts can be formed with chiral acids (e.g., single enantiomers such as 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.), chemically separated from the mixture to obtain the individual isomers, stepwise crystallization of the salts, followed by liberation of one or two of the separated bases, and optionally repeating the process to obtain one or two isomers substantially free of the other isomer, i.e., the desired stereoisomers having an optical purity of, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% by weight. Alternatively, the racemate can be covalently bound to a chiral compound (auxiliary) to obtain the diastereomers, as is well known to those skilled in the art.

[0173] As used herein, the term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also called prototropic tautomers) include interconversions via proton transfer, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions via rearrangement of some of the bonding electrons.

[0174] The compounds of the present invention can be prepared by various synthetic methods familiar to those skilled in the art, including the specific embodiments given below, embodiments in combination with other chemical synthetic methods, and equivalent alternative methods familiar to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present invention.

[0175] Technical and scientific terms not specifically defined herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0176] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. In the following examples, unless specific experimental conditions are given, the conventional conditions for such reactions or the conditions recommended by the manufacturer are usually followed. Percentages and parts are by weight unless otherwise stated. Liquid ratios are by volume unless otherwise stated.

[0177] Experimental materials and reagents used in the following examples may be obtained from commercial sources unless otherwise stated. Synthesis of Example A1

[0178] [ka]

[0179] Step 1: Preparation of compound A1-2 At room temperature, indium chloride (4.04 g, 18.27 mmol) was added to a solution of compound A1-1 (3 g, 15.23 mmol) and cyclopentanone (1.41 g, 16.75 mmol) dissolved in toluene (150 mL), and the mixture was heated to 120° C. and stirred for 24 hours. The mixture was cooled to room temperature (25° C.), and an aqueous sodium hydroxide solution (2 M, 180.00 mL) was added. The reaction system was heated to 120° C. under an argon gas atmosphere and stirred for 24 hours. The reaction mixture was cooled to room temperature (25° C.), extracted with a mixture of chloroform / isopropyl alcohol (v / v=3:1) (200 mL×5), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was slurried with a mixture of petroleum ether / ethyl acetate (v / v=2:1) ​​(20 mL), filtered, and the cake was dried to obtain compound A1-2, which was directly used in the next step reaction without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.40 (s, 1H), 7.70 - 7.48 (m, 2H), 6.55 (s, 2H), 2.88 (t, J = 7.6 Hz, 2H), 2.80 (t, J = 7.3H z, 2H), 2.13 - 1.91 (m, 2H). MS (ESI) m / z (M+ H) + =263.0.

[0180] Step 2: Preparation of compound A1-3 Compound 4-fluorobenzoylacetonitrile (25 g, 153.23 mmol) was dissolved in ethanol (1000 mL) and iodine (38.89 g, 153.23 mmol) was added to the ethanol (1000 mL), and the temperature was raised to 70 ° C. and stirred for 15 minutes, and the reaction system was cooled to room temperature (25 ° C.). Pyridine (12.12 g, 153.23 mmol, 12.37 mL) and thiourea (23.33 g, 306.47 mmol) were dissolved in ethanol (300 mL), and then slowly added to the above reaction system and stirred at room temperature (25 ° C.) for 1 hour. After the reaction was completed, ice-saturated sodium thiosulfate (500 mL) was added, filtered, the cake was washed with water, and dried to obtain compound 2-amino-4-(4-fluorophenyl)-5-cyanothiazole, which was used directly in the next step without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.25 (s, 2H), 8.11 - 7.86 (m, 2H), 7.50 - 7.30 (m, 2H).

[0181] Compound 2-amino-4-(4-fluorophenyl)-5-cyanothiazole (52g, 237.19mmol) and cuprous chloride (38.27g, 284.62mmol) were dissolved in acetonitrile (500mL), and tert-butyl nitrite (36.69g, 355.78mmol, 42.32mL) was added thereto. Under a nitrogen gas atmosphere, the reaction system was stirred at room temperature (25℃) for 0.5 hours, 1N HCl (300mL) was added thereto, and the mixture was separated and extracted with ethyl acetate (500mL) and water (100mL). The organic phases were combined, washed with saturated saline (100mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v)=0~1%) to obtain compound A1-3. 1 H NMR (400MHz, DMSO-d6) δ 8.24 - 8.00 (m, 2H), 7.57 - 7.23 (m, 2H).

[0182] Step 3: Preparation of Compound A1-4 Sodium hydride (90 mg, 2.25 mmol, purity: 60%) and compound A1-3 (280 mg, 1.17 mmol) were added to tetrahydrofuran (10 mL) in which compound A1-2 (300 mg, 1.14 mmol) was dissolved, and the mixture was stirred at room temperature (25 ° C.) for 16 hours. After the reaction was completed, saturated aqueous ammonium chloride solution (1 mL) and water (20 mL) were added to quench the reaction, and the mixture was extracted with ethyl acetate (40 mL). The organic phases were combined and washed with saturated saline (30 mL), then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by silica gel column chromatography (ethyl acetate / petroleum ether (v / v) = 0 to 60%) to obtain compound A1-4. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.48 (br s, 1H), 8.07 (d, J = 2.0 Hz, 1H), 7.99 - 7.92 (m, 3H), 7.78 (dd, J = 2.1, 8.9 Hz, 1H), 7.08 - 6.98 (m, 2H), 3.23 (t, J = 7.5 Hz, 2H), 3.05 (t, J = 7.4 Hz, 2H), 2.34 - 2.20 (m, 2H). MS (ESI) m / z (M+ H) + =464.9.

[0183] Step 4: Preparation of Compound A1-5 Methyl iodide (228.00 mg, 1.61 mmol) and potassium carbonate (150 mg, 1.09 mmol) were added to N,N-dimethylformamide (5 mL) containing compound A1-4 (250 mg, 537.24 μmol) at room temperature (25° C.), and the mixture was stirred at room temperature (25° C.) for 5 hours under a nitrogen gas atmosphere. After the reaction was completed, ice water (50 ml) was added to the reaction system. L) was added, a precipitate was precipitated, filtered, the cake was collected, and after drying the cake, compound A1-5 was obtained, which was directly used in the next step reaction without further purification. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.18 - 8.08 (m, 2H), 8.01 (d, J = 8.9 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.81 (dd, J = 2.1, 8.9 Hz, 1H), 7.23 - 7.11 (m, 2H), 3.66 (s, MS (ESI) m / z (M+ H) + =479.1.

[0184] Step 5: Preparation of Compound A1-6 1-(tert-butoxycarbonyl)piperazine (250 mg, 1.34 mmol), compound A1-5 (250 mg, 521.52 μmol), sodium tert-butoxide (150.00 mg, 1.56 mmol), tris(dibenzylideneacetone)dipalladium(0) (100.00 mg, 109.20 μmol) and 2-(di-tert-butylphosphino)biphenyl (50.00 mg, 167.56 μmol) were dissolved in toluene (12 mL), and the reaction system was heated to 110° C. under a nitrogen gas atmosphere and stirred for 1 hour. The reaction system was filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v)=0-60%) to obtain compound A1-6. MS (ESI) m / z (M+ H) + =585.1.

[0185] Step 6: Preparation of Compound A1-7 Compound A1-6 (100 mg, 171.03 μmol) was dissolved in dioxane (2 mL) and hydrochloric acid in dioxane (4 M, 2 mL) was added and stirred at room temperature (25 ° C) for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure, ethyl acetate (20 mL) and water (10 mL) were added, and the pH was adjusted to 9 with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate (20 mL × 2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound A1-7, which was used directly in the next step without further purification. MS (ESI) m / z (M + H)+ = 485.1.

[0186] Step 7: Preparation of Compound A1-8 3-Hydroxycyclobutylamine (5.0 g, 45.64 mmol, HCl salt) and potassium carbonate (13.88 g, 100.41 mmol) were dissolved in water (32 mL) and dichloromethane (35 mL), and chloroacetyl chloride (5.15 g, 45.64 mmol) was added thereto under the condition of 0° C. After the addition was completed, the reaction system was stirred at room temperature (25° C.) for 16 hours. The reaction system was extracted with ethyl acetate / n-butanol (v / v=1 / 1) (40 mL×9), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound A1-8, which was used directly in the next step reaction without further purification. 1 H NMR (400MHz, CHLOROFORM-d) δ 4.73 (br s, 1H), 4.55 - 4.47 (m, 1H), 4.38 - 4.27 (m, 1H), 4.23 - 4.11 (m, 1H), 3.96 (dd, J = 3.8, 11.0 Hz, 1H), 3.92 (s, 2H), 3.21 (br s, 1H).

[0187] Step 8: Preparation of Compound A1 Compound A1-7 (83 mg, 171.28 μmol), compound A1-8 (51 mg, 340.97 μmol) and potassium carbonate (71 mg, 513.73 μmol) were dissolved in acetonitrile (3 mL) and stirred at room temperature (25° C.) for 16 hours. After dilution with water (20 mL) and ethyl acetate (50 mL), the liquid was separated, the organic phases were combined, washed with saturated saline (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give A crude product was obtained, and the crude product was purified by preparative high performance liquid chromatography (separation conditions: column: Phenomenex Gemini-NX 80 × 30 mm × 3 μm; column temperature: 25 ° C; mobile phase: water (10 mM ammonium bicarbonate)-acetonitrile; acetonitrile: 40% to 70%, 9 min) to obtain compound A1. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.16 (br s, 2H), 8.00 (d, J = 9.3 Hz, 1H), 7.48 (dd, J = 2.3, 9.4 Hz, 1H), 7.18 (t, J = 8.5 Hz, 2H), 6.88 (d, J = 2.2 Hz, 1H), 4.73 - 4.64 (m, 1H), 4.51 - 4.40 (m, 1H), 4.33 - 4.25 (m, 1H), 4.11 (br dd, J = 3.6, 9.8 Hz, 1H), 3.90 (br dd, J = 3.9, 10.9 Hz, 1H), 3.66 (s, 3H), 3.31 (br s, 4H), 3.21 (dt, J = 4.1, 7.6 Hz, 2H), 3.10 (s, 2H), 3.04 - 2.93 (m, 2H), 2.69 (br d, J = 4.4 Hz, 4H), 2.29 - 2.22 (m, 2H). MS (ESI) m / z (M+H) + =598.2. HPLC retention time 6.39min.

[0188] Separation conditions: Column: WELCH Ultimate LP-C18 150×4.6 mm, 5 μm; Column temperature: 40° C.; Mobile phase: water (2.75 mL / 4 L trifluoroacetic acid)-acetonitrile (2.5 mL / 4 L trifluoroacetic acid); Acetonitrile: 10%-80% 10 min, 80% 5 min; Flow rate: 1.5 mL / min.

[0189] The following Examples A2 to A38 were synthesized in the same manner as in the synthesis of Example A1, as shown in Table 1 below.

[0190] [Table 1] TIFF2024543167000072.tif230159TIFF2024543167000073.tif240159TIFF2024543167000074.tif241159TIFF2024543 167000075.tif238159TIFF2024543167000076.tif237159TIFF2024543167000077.tif240159TIFF2024543167000078.t if240159TIFF2024543167000079.tif238159TIFF2024543167000080.tif243159TIFF2024543167000081.tif239159TIF F2024543167000082.tif239159TIFF2024543167000083.tif239159TIFF2024543167000084.tif238159TIFF20245431670 00085.tif231159TIFF2024543167000086.tif231159TIFF2024543167000087.tif240159TIFF2024543167000088.tif23 7159TIFF2024543167000089.tif238159TIFF2024543167000090.tif238159TIFF2024543167000091.tif219159TIFF202 4543167000092.tif224159TIFF2024543167000093.tif216159TIFF2024543167000094.tif237159TIFF20245431670000 95.tif238159TIFF2024543167000096.tif238159TIFF2024543167000097.tif237159TIFF2024543167000098.tif147159

[0191] A20 Synthesis of intermediate 5-amino-2-chloroisonicotinonitrile Under an argon gas atmosphere, 3-amino-4-cyanopyridine (1.5 g, 12.59 mmol) was dissolved in N,N-dimethylformamide (15 mL) and N-chlorosuccinimide (1.68 g, 12.59 mmol) was added, and the mixture was stirred at room temperature (20 ° C) for 18 hours. After the reaction was completed, the reaction system was poured into water (20 mL) and extracted with ethyl acetate (50 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0 ~ 50%) to obtain the compound 5-amino-2-chloroisonicotinonitrile. MS (ESI) m / z (M + 1) + =153.8.

[0192] Synthesis of Example A22

[0193] [ka]

[0194] Step 1: Preparation of compound A22-2 The compound bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, 1-methyl ester (2 g, 11.75 mmol) was dissolved in water (20 mL) and sodium hydroxide (611.14 mg, 15.28 mmol) was added, and the mixture was heated to 100° C. and stirred for 1 hour. After washing with methyl-tert-butyl ether (5 mL), the pH was adjusted to 3 with concentrated hydrochloric acid, and extracted with ethyl acetate (50 m×6). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain A22-2, which was used directly in the next step reaction without further purification. 1 H NMR (400MHz, DEUTERIμM OXIDE) δ = 2.15 (s, 1H)

[0195] Step 2: Preparation of compound A22-3 A22-2 (1.4 g, 8.97 mmol) was dissolved in water (15 mL) and Selectfluor (7.94 g, 22.42 mmol) and silver nitrate (152.31 mg, 896.66 μmol) were added thereto. After the addition was completed, the reaction was heated to 65° C. and stirred for 16 hours. The reaction was filtered and extracted with methyl tert-butyl ether (3×30 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give compound A22-3, which was used directly in the next step reaction without further purification. 1 H NMR (400MHz, CHLOROFORM-d) δ = 2.42 (d, J=2.3 Hz, 1H); 19 F NMR (376MHz, CHLOROFORM-d) δ = -149.78 (s, 1F)

[0196] Step 3: Preparation of compound A22-4 A22-3 (800 mg, 6.15 mmol) was dissolved in anhydrous dichloromethane (25 mL) and methanol (1 mL), and trimethylsilyldiazomethane (2 M, 4.61 mL) was added and stirred at room temperature (25 ° C.) for 24 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain compound A22-4, which was directly used in the next step without further purification.

[0197] Step 4: Preparation of compound A22-5 Acetonitrile (284.80 mg, 6.94 mmol) was added to a solution of n-butyllithium (2.5 M, 2.78 mL) in tetrahydrofuran (10 mL) under the condition of -70°C, and after the addition was completed, the reaction system was stirred at -30°C for 0.5 hours. A22-4 (0.5 g, 3.47 mmol) was added dropwise to the reaction system, and after the addition was completed, the reaction system was stirred at room temperature (25°C) for 4 hours. The reaction system was quenched by adding a saturated aqueous solution of ammonium chloride (1 mL), extracted with ethyl acetate (3 x 30 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound A22-5, which was used directly in the next step reaction without further purification. 1H NMR (400MHz, CHLOROFORM-d) δ = 3.56 (s, 2H), 2.50 (d, J=2.3 Hz, 6H)

[0198] Step 5: Preparation of compound A22-6 Pyridine (258.24 mg, 3.26 mmol) was added to A22-5 (500 mg, 3.26 mmol) in ethanol (10 mL), and the mixture was stirred at 70° C. for 15 minutes, and then cooled to room temperature (25° C.). Then, a solution of iodine (828.61 mg, 3.26 mmol, 657.63 Ul) and thiourea (497.02 mg, 6.53 mmol) in ethanol (3 mL) was slowly added. After the addition was completed, the reaction was stirred at room temperature (25° C.) for 1 hour. The reaction was quenched by adding a saturated aqueous solution of ammonium chloride (1 mL) and saturated sodium thiosulfate (1 mL). The reaction was concentrated to remove most of the solvent, diluted with water (10 mL), extracted with ethyl acetate (3×30 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0-60%) to give A22-6. 1 H NMR (400MHz, CHLOROFORM-d) δ = 5.55 (br s, 2H), 2.56 (d, J=2.4 Hz, 6H); 19 F NMR (376MHz, CHLOROFORM-d) δ = -148.50 (s, 1F), MS (ESI) m / z (M+1) + =209.9.

[0199] Step 6: Preparation of compound A22-7 A22-6 (0.12 g, 573.50 μmol) was dissolved in acetonitrile (5 mL), and tert-butyl nitrite (88.71 mg, 860.24 μmol) and copper chloride (92.53 mg, 688.20 μmol) were added and stirred at room temperature (20 ° C) for 1 hour. 1N HCl (1 mL) was added thereto to quench, and then the mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0 ~ 10%) to obtain A22-7.

[0200] Steps 7-10: Preparation of compound A22 A22 was synthesized similarly to Example A1. 1 H NMR (400MHz, CHLOROFORM-d) δ = 7.19 (dd, J=2.4, 13.2 Hz, 1H), 6.63 (d, J=1.8 Hz, 1H), 4.73 (br s, 1H), 4.54 - 4.43 (m, 1H), 4.33 (dd, J=6.6, 11.0 Hz, 1H), 4.14 (br d, J=9.8 Hz, 1H), 3.94 (dd, J=4.1, 10.8 Hz, 1H), 3.56 (s, 3 H), 3.37 - 3.29 (m, 4H), 3.25 (dt, J=2.2, 7.6 Hz, 2H), 3.13 (s, 2H), 2.96 (t, J=7.3 Hz, 2H), 2.72 (br d, J=4.1 Hz, 4H), 2.59 (d, J=2. 4 Hz, 6H), 2.39 (br s, 1H), 2.25 (quin, J=7.6 Hz, 2H).

[0201] MS (ESI) m / z (M+1) + =606.3. HPLC retention time: 3.56min. Separation conditions: Column: Ultimate C18 3.0×50 mm, 3 μm; Column temperature: 40° C.; Mobile phase: water (2.75 mL / 4 L trifluoroacetic acid)-acetonitrile (2.5 mL / 4 L trifluoroacetic acid); Acetonitrile: 10%-80% 6 min, 80% 2 min; Flow rate: 1.2 mL / min.

[0202] Synthesis of Example A36

[0203] [ka]

[0204] Step 1: Preparation of compound A36-2 Compound A36-1 (10 g, 64.45 mmol) was dissolved in concentrated hydrochloric acid (50 mL), and sodium nitrite (8.89 g, 128.90 mmol) was added thereto at 0 ° C., and the mixture was stirred for 10 minutes while maintaining the temperature. Then, potassium iodide (26.75 g, 161.13 mmol) was added, and the reaction system was stirred at 0 ° C. for 1 hour. After the reaction was completed, the reaction system was quenched by adding saturated aqueous sodium bicarbonate solution (150 mL) and saturated sodium thiosulfate (50 mL), extracted with ethyl acetate (150 mL × 3), washed with saturated saline (150 mL × 3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 25%) to obtain 7.52 g of compound A36-2, with a yield of 42%. MS (ESI) m / z (M + H) + =266.8.

[0205] Step 2: Preparation of compound A36-3 Compound A36-2 (5.5 g, 20.67 mmol) and p-methoxybenzyl chloride (4.86 g, 31.01 mmol, 4.22 mL) were dissolved in anhydrous N,N-dimethylformamide (50 mL), potassium carbonate (8.57 g, 62.02 mmol) was added thereto at 0° C., and the reaction system was stirred at room temperature (25° C.) for 18 hours. After the reaction was completed, water (100 mL) was added to dilute the reaction system, extracted with ethyl acetate (100 mL×3), washed with saturated saline (100 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate and filtered. Concentration gave the crude product, which was purified by silica gel column chromatography (ethyl acetate / petroleum ether=10%) to give 5.9 g of compound A36-3, with a yield of 67%. MS (ESI) m / z (M+ H) + =386.9.

[0206] Step 3: Preparation of compound A36-4 Compound A36-3 (3.9 g, 10.10 mmol), 4-chloro-2-fluoroaniline (2.21 g, 15.15 mmol) and 1,4-dioxane (40 mL) were added in sequence to a 100 mL one-neck flask, the reaction system was replaced with argon gas three times, and tris(dibenzylideneacetone)dipalladium(0) (924.77 mg, 1.01 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.17 g, 2.02 mmol) and cesium carbonate (6.58 g, 20.20 mmol) were added in sequence under an argon gas atmosphere, and the reaction was carried out at 100° C. for 2 hours. After the reaction was completed, the mixture was allowed to cool to room temperature (25°C), and then filtered through diatomaceous earth. Water (50mL) was added to the filtrate, which was then extracted with ethyl acetate (50mL x 3), washed with saturated saline, and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 5%) to obtain 2.90g of compound A36-4, with a yield of 71%. 1H NMR (400MHz, CDCl3) δ = 8.38 - 8.28 (m, 2H), 7.59 (s, 1H), 7.46 - 7.39 (m, 1H), 7.26 - 7.23 (m, 1H), 7.14 - 7.05 (m, 2H), 6.95 - 6.86 (m, 2H), 5.13 (s, 2H), 4.29 (q, J = 7.2 Hz, 2H), 3.81 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H).

[0207] Step 4: Preparation of compound A36-5 Compound A36-4 (2.8 g, 6.93 mmol) was dissolved in a mixed solvent of methanol (10 mL) and tetrahydrofuran (10 mL), and then sodium hydroxide solution (8 M, 2.60 mL) was slowly added dropwise at 0 ° C under nitrogen gas atmosphere. After the addition was completed, the reaction system was stirred at 70 ° C for 3 hours. After the reaction was completed, water (20 mL) was added to dilute the mixture, and the pH was adjusted to 3-5 with 1N hydrochloric acid solution, and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product compound A36-5, which was used directly in the next step reaction without purification. MS (ESI) m / z (M + H) + =375.8.

[0208] Step 5: Preparation of compound A36-6 Crude product compound A36-5 (2.6 g, 6.93 mmol) and Eaton's reagent (50 mL) were added in sequence to a 100 mL one-neck flask, and the reaction system was stirred at 80 ° C for 2 hours. After the temperature of the reaction system returned to room temperature (25 ° C), the reaction solution was slowly added dropwise to water (300 mL), the pH was adjusted to 9 with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate (300 mL × 3), the organic phases were combined, dried by adding sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (methanol / ethyl acetate = 10%) to obtain 900 mg of compound A36-6. MS (ESI) m / z (M + H) + =238.0.

[0209] Step 6: Preparation of compound A36-7 Compound A36-6 (900 mg, 3.8 mmol) was dissolved in 1,4-dioxane (20 mL), and phosphorus oxychloride (1.41 mL, 15.2 mmol) was slowly added thereto at room temperature (25 ° C.), and the reaction system was reacted at 80 ° C. for 1 hour. After the temperature of the reaction system returned to room temperature (25 ° C.), the reaction solution was slowly poured into ice water (200 mL), extracted with ethyl acetate (3 × 80 mL), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product compound A36-7 was obtained without purification and used directly in the next step reaction. MS (ESI) m / z (M+ H) + =256.0.

[0210] Step 7: Preparation of compound A36-8 Compound A36-7 (921 mg, 3.60 mmol) was dissolved in tetrahydrofuran (10 mL) solution, and 4-dimethylaminopyridine (43.94 mg, 359.68 μmol), di-tert-butyl dicarbonate (1.57 g, 7.19 mmol, 1.65 mL) and triethylamine (1.09 g, 10.79 mmol, 1.50 mL) were added thereto at 0° C. The reaction system was reacted at room temperature (25° C.) for 1 hour. The reaction solution was concentrated, and the crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether=10%) to obtain 680 mg of compound A36-8. 1 H NMR (400MHz, CHLOROFORM-d) δ = 8.49 (s, 1H), 8.18 (s, 1H), 7.59 (dd, J = 2.1, 9.5 Hz, 1H), 1.78 (s, 9H). MS (ESI) m / z (M+H) + =256.0.

[0211] Steps 8-12: Preparation of compound A36 A36 was synthesized similarly to Example A1. 1H NMR (400MHz, METHANOL-d4) δ = 8.29 (s, 1H), 8.34 - 8.23 ​​(m, 1H), 8.08 (br s, 2H), 7.62 (br d, J = 16.3 Hz, 1H), 7.22 (t, J = 8.8 Hz, 2H), 6.87 (s, 1H), 4.60 (s, 5H), 4.57 (br s, 1H), 4.51 - 4.45 (m, 1H), 4.25 - 4.18 (m, 1H), 4.08 - 4.02 (m, 1H), 3.89 (s, 3H), 3.77 (br d, J = 10.0 Hz, 1H), 3.11 (d, J = 3.8 Hz, 2H), 2.67 (br d, J = 4.8 Hz, 4H). MS (ESI) m / z (M+ H) + =616.2. HPLC retention time: 3.51min.

[0212] Separation conditions: Column: Ultimate C18 3.0×50 mm, 3 μm; Column temperature: 40°C; Mobile phase: water (2.75 mL / 4 L trifluoroacetic acid)-acetonitrile (2.5 mL / 4 L trifluoroacetic acid); Acetonitrile: 10%-80% 6 min, 80% 2 min; Flow rate: 1.2 mL / min. Synthesis of Example B1

[0213] [ka]

[0214] Step 1: Preparation of compound B1-2 Compound B1-1 (1 g, 4.62 mmol) and imidazole (629.54 mg, 9.25 mmol) were dissolved in dichloromethane (20 mL), and tert-butyldiphenylchlorosilane (1.40 g, 5.09 mmol) was added dropwise thereto under the condition of 0 ° C. After completion of the dropwise addition, the reaction system was warmed to room temperature (25 ° C.) and stirred for 2 hours. The reaction system was diluted with saturated sodium bicarbonate (25 mL), extracted with dichloromethane (50 mL × 3), the organic phase was combined, washed with saturated saline (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by silica gel column chromatography (ethyl acetate / petroleum ether (v / v) = 0 ~ 40%) to obtain compound B1-2. 1 H NMR (400MHz, CHLOROFORM-d) δ 7.72 - 7.57 (m, 4H), 7.49 - 7.35 (m, 6H), 3.94 (br s, 2H), 3.67 - 3.50 (m, 2H), 3.01 (br MS (ESI) m / z (M+H) + = 455.6.

[0215] Step 2: Preparation of compound B1-3 Compound B1-2 (569.10 mg, 1.25 mmol), compound A1-5 (300 mg, 625.83 μmol), sodium tert-butoxide (120.29 mg, 1.25 mmol), tris(dibenzylideneacetone)dipalladium(0) (34.38 mg, 37.55 μmol) and 2-(di-tert-butylphosphino)biphenyl (18.67 mg, 62.58 μmol) were dissolved in toluene (1 mL), and the reaction system was heated to 115 ° C. under a nitrogen gas atmosphere and stirred for 2 hours. The reaction system was filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0 ~ 25%) to obtain compound B1-3. MS (ESI) m / z (M + H) + =853.2.

[0216] Step 3: Preparation of Compound B1-4 A solution of hydrochloric acid in dioxane (4 M, 3 mL) was added to dioxane (3 mL) in which compound B1-3 (100 mg, 117.22 μmol) had been dissolved, and the mixture was stirred at room temperature (25° C.) for 2 hours. After completion of the reaction, the reaction system was quenched by adding saturated sodium bicarbonate (20 mL). The mixture was extracted with ethyl acetate (20 mL x 3), and the organic phases were combined and washed with saturated saline (20 mL x 3), then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound B1-4, which was directly used in the next step reaction without further purification. MS (ESI) m / z (M+H) + = 753.4.

[0217] Step 4: Preparation of compound B1-5 Compound B1-4 (70 mg, 92.96 μmol) was dissolved in dichloromethane (10 mL), and triethylamine (32.70 mg, 323.19 μmol) and methanesulfonyl chloride (37.32 mg, 325.83 μmol) were added thereto under the condition of 0° C. After the addition was completed, the reaction system was stirred at room temperature (25° C.) for 1 hour under nitrogen gas atmosphere. Under the condition of 0° C., the reaction system was quenched by adding saturated sodium bicarbonate (10 mL), extracted with ethyl acetate (20 mL×3), the organic phase was combined, washed with saturated saline (20 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound B1-5, which was used directly in the next step reaction without further purification. MS (ESI) m / z (M+H) + = 831.3.

[0218] Step 5: Preparation of Compound B1 A tetrahydrofuran (6 mL) solution containing compound B1-5 (80 mg, 96.26 μmol) and tetra-n-butylammonium fluoride (1 M, 105.88 Ul) was stirred for 1 hour at room temperature (25 ° C.) under a nitrogen gas atmosphere. After the reaction was completed, water (20 mL) was added to dilute the mixture, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined and washed with saturated saline (20 mL × 6), then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by preparative high-performance liquid chromatography (separation conditions: column: Phenomenex Gemini-NX 80 × 30 mm × 3 μm; column temperature: 25 ° C.; mobile phase: water (10 Mm ammonium bicarbonate)-acetonitrile; acetonitrile: 37% to 67% 9 min) to obtain compound B1. 1 H NMR (400MHz, DMSO-d6) δ 8.05 (br s, 2H), 7.91 (br d, J = 9.0 Hz, 1H), 7.62 (br d, J = 9.0 Hz, 1H), 7.40 (br s, 2H), 6.92 (br s, 1H), 4.82 (br d, J = 19.8 Hz, 1H), 4.07 (br s, 1H), 3.77 - 3.67 (m, 2H), 3.61 (br s, 5H), 3.08 (br d, J = 7.5 Hz, 4H), 2.99 (br d, J = 10.3 Hz, 2H), 2.91 (br d, J = 3.5 Hz, 5H), 2.15 (br d, J = 6.8 Hz, 2H). MS (ESI) m / z (M+ H) + =593.2. HPLC retention time 3.90min.

[0219] Separation conditions: Column: Ultimate C18 3.0×50 mm, 3 μm; Column temperature: 40° C.; Mobile phase: water (2.75 mL / 4 L trifluoroacetic acid)-acetonitrile (2.5 mL / 4 L trifluoroacetic acid); Acetonitrile: 10%-80% 6 min, 80% 2 min; Flow rate: 1.2 mL / min.

[0220] The following Examples B2 to B4 were synthesized in the same manner as in the synthesis of Example B1, as shown in Table 2 below.

[0221] [Table 2] TIFF2024543167000103.tif236159TIFF2024543167000104.tif70159

[0222] Synthesis of Example C1

[0223] [ka]

[0224] Step 1: Preparation of compound C1-2 Compound C1-1 (5 g, 36.73 mmol) was dissolved in N,N-dimethylformamide (100 mL) and N-bromosuccinimide (6.54 g, 36.73 mmol) was added and stirred at room temperature (25 ° C) for 16 hours. After the reaction was completed, the reaction system was poured into ice water (500 mL) and a precipitate was precipitated. The precipitate was filtered and the cake was collected and dried to obtain the crude product compound C1-2, which was directly used in the next step reaction. 1 H NMR (400MHz, DMSO-d6) δ 7.60 (dd, J = 2.2, 11.0 Hz, 1H), 7.53 (s, 1H), 6.41 (s, 2H).

[0225] Step 2: Preparation of compound C1-3 Indium chloride (6.17 g, 27.90 mmol) was added to a solution of compound C1-2 (5 g, 23.25 mmol) and cyclopentanone (2.15 g, 25.58 mmol, 2.26 mL) dissolved in toluene (150 mL), and the mixture was stirred at 120° C. for 24 hours. The mixture was cooled to room temperature (25° C.), and an aqueous solution of sodium hydroxide (2 M, 275.00 mL) was added. The mixture was heated to 120°C under argon gas and stirred for 24 hours. The reaction was cooled to room temperature (25°C), filtered, the cake was washed with ethyl acetate (100mL), the filtrate was extracted with ethyl acetate (200mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was slurried in a mixture of petroleum ether / ethyl acetate (v / v=1:1) (100mL), filtered, and the cake was dried to obtain the crude product compound C1-3, which was used directly in the next step reaction. 1 H NMR (400MHz, DMSO-d6) δ 8.25 (s, 1H), 7.56 (dd, J = 1.9, 10.5 Hz, 1H), 6.68 (s, 2H), 2.90 (t, J = 7.7 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H), 2.06 (quin, J = 7.5 Hz, 2H). MS (ESI) m / z (M+H) + =281.0.

[0226] Step 3: Preparation of compound C1-4 Under the condition of 0 ° C., compound C1-3 (1.4 g, 4.98 mmol) was dissolved in N,N-dimethylformamide (50 mL) and sodium hydride (600.00 mg, 15.00 mmol) was added, and the mixture was stirred for 10 minutes, and then compound A1-3 (1.43 g, 5.98 mmol) was added. After the addition was completed, the reaction system was warmed to room temperature (25 ° C.) and stirred for 2 hours. The reaction system was quenched by adding saturated aqueous ammonium chloride solution (10 mL) and water (200 mL), extracted with ethyl acetate (300 mL), and the organic phases were combined and washed with saturated saline (300 mL), then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was slurried in a mixture solvent (60 mL) of petroleum ether / ethyl acetate (v / v = 1:1), filtered, and the cake was dried to obtain a crude product compound C1-4, which was directly used in the next step reaction. 1 H NMR (400MHz, DMSO-d6) δ 11.27 (br s, 1H), 8.11 (s, 1H), 7.99 - 7.89 (m, 2H), 7.84 (dd, J = 1.9, 10.0 Hz, 1H), 7.35 (t, J = 8.9 Hz, 2H), 3.11 (t, J = 7.5 Hz, 2H), 2.88 (br t, J = 7.2 Hz, 2H), 2.11 (quin, J = 7.4 Hz, 2H). MS (ESI) m / z (M+ H) + =483.0.

[0227] Step 4: Preparation of compound C1-5 Methyl iodide (2.01 g, 14.17 mmol, 882.17 Ul) and potassium carbonate (1.97 g, 14.22 mmol) were added to compound C1-4 (2.29 g, 4.74 mmol) dissolved in N,N-dimethylformamide (30 mL) at room temperature (25 ° C). After the addition was completed, the reaction system was stirred at room temperature (25 ° C) for 3 hours under nitrogen gas atmosphere. Ice water (200 mL) was added to the reaction system, and a precipitate was precipitated. The precipitate was filtered and the cake was collected. After drying the cake, the crude product compound C1-5 was obtained and used directly in the next step reaction. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.17 - 8.06 (m, 2H), 7.71 (d, J = 1.5 Hz, 1H), 7.61 - 7.52 (m, 1H), 7.16 (t, J = 8.5 Hz, 2H), 3.65 (s, 3H), 3.32 - 3.28 (m, 2H), 3.07 - 3.02 (m, 2H), 2.36 - 2.23 (m, 2H). MS (ESI) m / z (M+ H) + =479.1.

[0228] Step 5: Preparation of compound C1-6 Under an argon gas atmosphere, compound C1-5 (380 mg, 764.04 μmol), compound tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (454.44 mg, 2.29 mmol), sodium tert-butoxide (220 mg, 2.29 mmol), tris(dibenzylideneacetone)dipalladium(0) (140 mg , 152.81μmol) and 2-(di-tert-butylphosphino)biphenyl (88mg, 152.81μmol) dissolved in toluene (6mL) were heated to 100℃ and stirred for 3 hours. After cooling the reaction system to room temperature (25℃), it was filtered, the filtrate was concentrated, the residue was diluted with ethyl acetate (20mL), washed with saturated saline (10mL×2), the organic phase was combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (methanol / dichloromethane (v / v)=0-5%) to obtain compound C1-6. 1 H NMR (400MHz, Chloroform-d) δ 8.17 (br d, J = 5.5 Hz, 2H), 7.18 (br t, J = 8.6 Hz, 2H), 6.76 - 6.61 (m, 1H), 6.17 (s, 1H), 4.22 - 4.03 (m, 8H), 3.68 - 3.59 (m, MS (ESI) m / z (M+ H) + =615.3.

[0229] Step 6: Preparation of compound C1-7 Compound C1-6 (300 mg, 488.04 μmol) was dissolved in dichloromethane (4 mL) and trifluoroacetic acid (1.54 g, 13.51 mmol) was added, and the mixture was stirred at room temperature (20 ° C) for 2 hours. Ethyl acetate (20 mL) and water (10 mL) were added, the pH was adjusted to 9 with saturated aqueous sodium bicarbonate, and the mixture was extracted with ethyl acetate (20 mL × 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by silica gel column chromatography (methanol / dichloromethane (v / v) = 0 ~ 7%) to obtain compound C1-7. MS (ESI) m / z (M + H) + =515.1.

[0230] Step 7: Preparation of compound C1 Compound C1-7 (25 mg, 48.58 μmol) and (S)-tetrahydro-3-furan carboxylic acid (10 mg, 86.12 μmol) were dissolved in N,N-dimethylformamide (1 mL) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (33 mg, 86.79 μmol) and N,N-diisopropylethylamine (37.10 mg, 287.06 μmol) were added. After the addition was completed, the reaction system was stirred at room temperature (25 °C) for 2 hours. Ethyl acetate (50 mL) and water (20 mL) were added thereto, and the organic phase was washed with saturated saline (20 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by preparative high performance liquid chromatography (separation conditions: column: Phenomenex Gemini-NX 80 x 30 mm x 3 μm; column temperature: 25°C; mobile phase: water (10 Mm ammonium bicarbonate)-acetonitrile; acetonitrile: 46% to 76% 9 min) to obtain compound C1. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.22 - 8.10 (m, 2H), 7.18 (t, J = 8.5 Hz, 2H), 6.70 (dd, J = 2.3, 11.8 Hz, 1H), 6.19 (s, 1H), 4.40 - 4.31 (m, 2H), 4.21 (s, 2H), 4.15 - 4.08 (m, 4H), 4.02 - 3.96 (m, 1H), 3.94 - 3.77 (m, 3H), 3.63 (s, 3H), 3.27 - 3.22 (m, 2H), 3.00 (br t, J = 7.0 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.29 - 2.22 (m, 2H), 2.20 - 2.06 (m, 2H). MS (ESI) m / z (M+ H) + =613.1. HPLC retention time: 4.392min.

[0231] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 5 0mm; column temperature: 50°C; mobile phase: water (0.2mL / 1L of ammonia water)-acetonitrile; acetonitrile: 10%~80% 6min, 80% 2min; flow rate: 0.8mL / min.

[0232] The following Examples C2 to C35 were synthesized in the same manner as in Example C1, as shown in Table 3 below.

[0233] [Table 3] TIFF2024543167000107.tif237159TIFF2024543167000108.tif237159TIFF2024543167000109.tif21 0159TIFF2024543167000110.tif237159TIFF2024543167000111.tif238159TIFF2024543167000112.t if237159TIFF2024543167000113.tif238159TIFF2024543167000114.tif234159TIFF20245431670001 15.tif237159TIFF2024543167000116.tif238159TIFF2024543167000117.tif238159TIFF20245431670 00118.tif238159TIFF2024543167000119.tif238159TIFF2024543167000120.tif238159TIFF2024543 167000121.tif238159TIFF2024543167000122.tif231159TIFF2024543167000123.tif237159TIFF202 4543167000124.tif237159TIFF2024543167000125.tif238159TIFF2024543167000126.tif231159TIF F2024543167000127.tif238159TIFF2024543167000128.tif238159TIFF2024543167000129.tif119159

[0234] Synthesis of Example D1

[0235] [ka]

[0236] Step 1: Preparation of compound D1-2 To a solution of compound D1-1 (10 g, 58.13 mmol) and diethyl oxalpropionate (11.75 g, 58.13 mmol, 10.78 mL) in toluene (250 mL) was added p-toluenesulfonic acid (553 mg, 2.91 mmol). After the addition was complete, the reaction was heated to reflux (130 °C) using a Dean-Stark trap and stirred for 16 h. The reaction was cooled to room temperature (25 °C), filtered, the cake was washed with toluene, and the filtrate was concentrated to give compound D1-2, which was directly used in the next step reaction without further purification. Used for.

[0237] Step 2: Preparation of compound D1-3 Compound D1-2 (10 g, 28.07 mmol) was dissolved in polyphosphoric acid (30 g), and after the addition was completed, the reaction system was heated to 120°C and stirred for 3 hours. After the reaction was completed, aqueous sodium hydroxide solution (2 M) was added to quench the reaction, and a yellow solid precipitated. The mixture was filtered, and the cake was slurried with ethyl acetate (500 mL), filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0-50%; methanol / dichloromethane (v / v) = 0-20%) to obtain compound D1-3. 1 H NMR (400MHz, DMSO-d6) δ 11.89 (s, 1H), 8.16 (d, J = 1.9 Hz, 1H), 7.87 - 7.74 (m, 2H), 4.45 (q, J = 7.2 Hz, 2H), 2.20 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). MS (ESI) m / z (M+ H) + =309.7.

[0238] Step 3: Preparation of Compound D1-4 Compound D1-3 (2.09 g, 6.75 mmol) was dissolved in phosphorus oxychloride (33.00 g, 215.22 mmol, 20.00 mL), and after the addition was completed, the reaction system was heated to 110 ° C and stirred for 0.5 h. The reaction system was concentrated, diluted with water (30 mL), adjusted to pH > 7 with saturated sodium bicarbonate (30 mL), extracted with ethyl acetate (80 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0 ~ 12%) to obtain compound D1-4. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.30 (d, J = 2.1 Hz, 1H), 7.92 (d, J = 8.9 Hz, 1H), 7.72 (dd, J = 2.1, 8.9 Hz, 1H), 4.45 (q, J = 7.2 Hz, 2H), 2.67 - 2.49 (m, 3H), 1.39 (t, J = 7.2 Hz, 3H). MS (ESI) m / z (M+ H) + =327.7.

[0239] Step 4: Preparation of Compound D1-5 Compound A1-3 (3 g, 12.57 mmol) and triethylamine (6.54 g, 64.66 mmol, 9 mL) were dissolved in 1,4-dioxane (30 mL), and methylamine hydrochloride (2.55 g, 37.71 mmol) was added thereto at room temperature, and the mixture was stirred at 80°C for 2 hours to react. The reaction solution was spin-dried, then diluted with 100 mL of ethyl acetate, filtered, and the filtrate was washed with 100 mL of water, and the organic phase was dried, filtered, and spin-dried. The crude product was separated by silica gel column chromatography (petroleum ether / ethyl acetate = 30% to 50%) to obtain compound D1-5 (2.6 g, yield: 88.67%), which was a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ = 8.75 (br s, 1H), 8.12 - 7.93 (m, 2H), 7.37 (br t, J=8.9 Hz, 2H), 2.95 (br d, J=4.5 Hz, 3H)

[0240] Step 5: Preparation of Compound D1-6 Potassium carbonate (380 mg, 2.75 mmol) was added to N,N-dimethylformamide (10 mL) in which compound D1-4 (300 mg, 913.00 μmol) and compound D1-5 (300 mg, 1.29 mmol) were dissolved, and the mixture was heated to 130° C. under microwave conditions and stirred for 5 hours. After the reaction was completed, the reaction system was diluted with water (50 mL) and extracted with ethyl acetate (30 mL×3). The organic phases were combined and washed with saturated saline (50 mL), and then The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0-20%) to give compound D1-6. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.23 ​​- 8.08 (m, 3H), 7.94 - 7.85 (m, 2H), 7.24 - 7.07 (m, 2H), 4.57 (q, J = 7.2 Hz, 2H), 3.67 (s, 3H), 2.54 (s, 3H), 1.51 (t, J = 7.1 Hz, 3H). MS (ESI) m / z (M+ H) + =525.0.

[0241] Step 6: Preparation of Compound D1-7 Compound D1-6 (130 mg, 247.43 μmol) was dissolved in carbon tetrachloride (5 mL), and N-bromosuccinimide (73.11 mg, 410.74 μmol) and azobisisobutyronitrile (20.33 mg, 123.78 μmol) were added thereto. After the addition was completed, the reaction system was heated to 80° C. under an argon gas atmosphere and stirred for 16 hours. The reaction system was concentrated, the residue was diluted with water (50 mL), and then extracted with ethyl acetate (50 mL). The organic phases were combined, washed with saturated saline (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v)=0-30%) to obtain compound D1-7. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.21 (d, J = 8.8 Hz, 1H), 8.16 - 8.04 (m, 2H), 7.95 (dd, J = 1.8, 9.0 Hz, 1H), 7.86 (s, 1H), 7.16 (t, J = 8.4 Hz, 2H), 5.13 (d, J = 10.6 Hz, 1H), 4.72 (br d, J = 10.4 Hz, 1H), 4.68 - 4.54 (m, 2H), 3.75 (s, 3H), 1.56 - 1.50 (m, 3H). H) + =603.0.

[0242] Step 7: Preparation of Compounds D1-8 Compound D1-7 (100 mg, 165.48 μmol) was dissolved in acetonitrile (5 mL) and N,N-diisopropylethylamine (148.40 mg, 1.15 mmol, 200 uL) and ammonia in methanol (7 M, 1.00 mL) were added. After the addition was completed, the reaction was stirred at room temperature (20 °C) for 16 hours. After the reaction was completed, the crude product was concentrated under reduced pressure, slurried in a mixture of petroleum ether / ethyl acetate (v / v=3:1) (10 mL), filtered, and the cake was dried to obtain compound D1-8, which was used directly in the next step reaction without further purification. 1 H NMR (400MHz, DMSO-d6) δ 9.44 (br s, 1H), 8.35 - 8.25 (m, 2H), 8.09 (br d, J = 9.2 Hz, 1H), 7.91 (br s, 1H), 7.35 (br s, 2H), 4.70 - 4.59 (m, 1H), 4.50 - 4.38 (m, 1H), 3.68 (br s, 3H). MS (ESI) m / z (M+ H) + =494.0.

[0243] Step 8: Preparation of Compound D1-9 Compound D1-8 (100 mg, 202.29 μmol), 1-tert-butoxycarbonylpiperazine (150.00 mg, 805.37 μmol), tris(dibenzylideneacetone)dipalladium(0) (37.50 mg, 40.95 μmol), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (25.00 mg, 53.57 μmol) and sodium tert-butoxide (71.43 mg A solution of 743.27 μmol) dissolved in toluene (5 mL) was stirred at 100° C. for 1 hour under an argon gas atmosphere. After the reaction was completed, the reaction system was filtered and concentrated, and the residue was dissolved in ethyl acetate (20 mL) and washed with saturated saline (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was slurried in a mixed solvent of petroleum ether / ethyl acetate (v / v=5:1), filtered, and the cake was dried to obtain compound D1-9, which was directly used in the next step reaction without further purification. MS (ESI) m / z (M+ H) + =600.4.

[0244] Step 9: Preparation of Compound D1-10 Compound D1-9 (100 mg, 166.76 μmol) was dissolved in dichloromethane (4 mL) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL) was added. After the addition was completed, the mixture was stirred at room temperature (20 ° C) for 1 hour. After the reaction was completed, the reaction system was concentrated, the residue was dissolved in ethyl acetate (30 mL), washed with saturated sodium bicarbonate (10 mL) and saturated saline (10 mL) in sequence, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound D1-11, which was used directly in the next step reaction without further purification. MS (ESI) m / z (M+ H) + =500.1.

[0245] Step 10: Preparation of compound D1 Compound D1-10 (85 mg, 170.15 μmol) and compound A1-8 (51.00 mg, 340.97 μmol) were dissolved in acetonitrile (1 mL) and N,N-dimethylformamide (3 mL), and potassium carbonate (69 mg, 499.24 μmol) was added and stirred at room temperature (25 ° C.) for 24 hours. Saturated sodium bicarbonate aqueous solution (20 mL) and dichloromethane (20 mL) were added, the organic phase was combined, washed with saturated saline (20 mL), and then the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by preparative high performance liquid chromatography (separation conditions: column: Phenomenex Gemini-NX 80 × 40 mm × 3 μm; mobile phase: water (10 mM ammonium bicarbonate)-acetonitrile; acetonitrile: 30% to 60% 9 min) to obtain compound D1. 1 H NMR (400MHz, CHLOROFORM-d) δ 8.34 (d, J = 9.5 Hz, 1H), 8.15 - 8.10 (m, 2H), 7.67 - 7.62 (m, 1H), 7.17 (t, J = 8.5 Hz, 2H), 6.88 (d, J = 2.5 Hz, 1H), 6.65 (s, 1H), 4.71 (br s, 1H), 4.54 (s, 2H), 4.48 - 4.43 (m, 1H), 4.35 - 4.26 (m, 1H), 4.13 - 4.09 (m, 1H), 3.94 - 3.90 (m, 1H), 3.71 (s, 3H), 3.44 (br s, 4H), 3.12 (s, 2H), 2.72 (br s, 4H), 2.25 - 2.19 (m, 1H).MS (ESI) m / z (M+ H) + =613.1. HPLC retention time 2.934min.

[0246] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 50 mm; Column temperature: 50 °C; Mobile phase: water (0.2 mL / 1 L of ammonia water)-acetonitrile; Acetonitrile: 10%~80% 6 min, 80% 2 min; Flow rate: 0.8 mL / min.

[0247] Synthesis of Examples E1-a and E1-b

[0248] [ka]

[0249] Step 1: Preparation of compound E1-2 Compound C1-2 (1.8 g, 8.37 mmol) and compound E1-1 (900.00 mg, 9.17 mmol) were dissolved in toluene (20 mL) and p-toluenesulfonic acid (50 mg, 262.85 μmol) was added, and the mixture was heated to 140° C. and stirred for 2 hours. The reaction was concentrated to obtain compound E1-2, which was used directly in the next step without further purification. 1 H NMR (400MHz, DMSO-d6) δ = 8.02 (s, 1H), 7.92 - 7.83 (m, 2H), 6.55 (br d, J =1.8 Hz, 1H), 2.45 (br d, J=4.2 Hz, 4H). MS (ESI) m / z (M+1) +=295.0.

[0250] Step 2: Preparation of compound E1-3 Compound E1-2 (2.5 g, 8.47 mmol) was dissolved in tetrahydrofuran (20 mL), and lithium diisopropylamide (2 M, 12.8 mL) was added thereto. After the addition was completed, the reaction system was stirred at room temperature (25 ° C.) for 30 minutes under an argon gas atmosphere. Saturated ammonium chloride aqueous solution (10 mL) was added thereto, and then extracted with ethyl acetate (50 mL × 2). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by medium pressure column chromatography (methanol / dichloromethane (v / v) = 0 ~ 30%) to obtain compound E1-3. MS (ESI) m / z (M + 1) + =294.5.

[0251] Step 3: Preparation of compound E1-4 Sodium borohydride (50.00 mg, 1.32 mmol) was added to compound E1-3 (350 mg, 1.19 mmol) dissolved in tetrahydrofuran (5 mL) and methanol (5 mL) at room temperature, and the mixture was stirred for 1 hour. After the reaction was completed, water (20 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by medium pressure column chromatography (methanol / dichloromethane (v / v) = 0-30%). This was further purified to obtain compound E1-4. 1 H NMR (400MHz, DMSO-d6) δ = 8.29 (s, 1H), 7.61 (br d, J =10.8 Hz, 1H), 6.79 (s, MS (ESI) m / z (M+1) + =299.0.

[0252] Step 4: Preparation of compound E1-5 Compound E1-4 (130 mg, 437.53 μmol) was dissolved in dichloromethane (5 mL) and imidazole (65.00 mg, 954.80 μmol) and tert-butyldimethylsilyl chloride (78.00 mg, 517.52 μmol) were added and stirred at room temperature for 18 hours. After the reaction was completed, water (20 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (20 mL x 2). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by medium pressure column chromatography (ethyl acetate / petroleum ether (v / v) = 0-40%) to obtain compound E1-5. 1 H NMR (400MHz, DMSO-d6) δ = 8.28 (s, 1H), 7.59 (dd, J =1.5, 10.3 Hz, 1H), 6.80 (s, 2H), 5.11 (t, J =6.3 Hz, 1H), 2.94 - 2.57 (m, 2H), 2.45 - 2.35 (m, 1H), 1.93 - 1.81 (m, 1H). MS (ESI) m / z (M+1) + =411.1.

[0253] Step 5: Preparation of Compound E1-10 Compound E1-10 was synthesized in the same manner as in Example A1. MS (ESI) m / z (M+1) + =746.3.

[0254] Step 6: Preparation of compound E1 Compound E1-10 (80 mg, 107.25 μmol) was dissolved in tetrahydrofuran (2 mL), and tetra-n-butylammonium fluoride (1 M, 160 uL) was added thereto. After the addition was completed, the reaction system was stirred at room temperature (25 ° C.) for 2 hours. Water (20 mL) was added thereto to dilute, and then extracted with ethyl acetate (20 mL × 2). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by preparative high-performance liquid chromatography (separation conditions: column: Phenomenex Gemini-NX 80 × 30 mm × 3 μm; mobile phase: water (10 mM ammonium bicarbonate)-acetonitrile; acetonitrile: 42% to 72% 9 min) to obtain compound E1. 1 H NMR (400MHz, Chloroform-d) δ = 8.14 (br s, 2H), 7.24 - 7.13 (m, 2H), 7.24 - 7.13 (m, 1H), 6.66 (s, 1H), 5.44 - 5.31 (m, 1H), 4.70 (br s, 1H), 4.51 - 4.39 (m, 1H), 4.35 - 4.25 (m, 1H), 4.13 (br dd, J =4.1, 9.7 Hz, 1H), 3.92 (br d, J =7.5 Hz, 1H), 3.64 (s, 3H), 3.54 - 3.43 (m, 1H), 3.35 (br s, MS (ESI) m / z (M+1) + =632.2. HPLC retention time: 3.433min.

[0255] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 50 mm; Column temperature: 50 °C; Mobile phase: water (0.2 mL / 1 L of ammonia water)-acetonitrile; Acetonitrile: 10%~80% 6 min, 80% 2 min; Flow rate: 0.8 mL / min.

[0256] Step 7: Preparation of compounds E1-a and E1-b Compound E1 was purified by SFC (separation conditions: column: DAICEL CHIRALCEL OD H (250 mm × 30 mm, 5 μm); mobile phase: [CO2-methanol (0.1% aqueous ammonia)]; methanol %: 50%). After concentration, compound E1-a and compound E1-b were obtained. Compound E1-a: 1 H NMR (400MHz, Chloroform-d) δ = 8.15 (br s, 2H), 7.18 (br t, J =8.4 Hz, 2H), 6.66 (br s, 1H), 5.42 - 5.32 (m, 1H), 4.69 (br s, 1H), 4.46 (br s, 1H), 4.30 (br s, 1H), 4.11 (br d, J =6.4 Hz, 1H), 3.91 (br d, J =7.3 Hz, 1H), 3.65 (s, 2H), 3.33 (br s, 3H), 3.23 - 3.19 (m, 1H), 3.19 - 3.17 (m, 1H), 3.11 (br s, 1H), 3.22 - 3.01 (m, 1H), 2.98 - 2.81 (m, 2H), 2.69 (br s, 4H). MS (ESI) m / z (M+ H) + =632.6. SFC retention time: 7.004min.

[0257] Separation conditions: Column: DAICEL CHIRALCEL OD-H (250mm×30mm, 5μm); Column temperature: 35℃; Mobile phase: CO2-methanol (0.05% DEA); Methanol: 5%~40% 5min, 40% 2.5min, 5% 2.5min; Flow rate: 2.5mL / min. HPLC: Retention time 4.55min.

[0258] Separation conditions: カラム: 2min; flow rate: 1.2mL / min. Compound E1-b: 1 H NMR (400MHz, Methanol-d4) δ = 8.09 (br s, 2H), 7.45 (br d, J =14.1 Hz, 1H), 7.22 (br t, J =8.7 Hz, 2H), 6.79 (s, 1H), 5.33 - 5.17 (m, 1H), 4.58 (br s, 1H), 4.51 - 4.39 (m, 1H), 4.22 (dd, J =7.0, 10.3 Hz, 1H), 4.04 (br d, J =7.3 Hz, 1H), 3.85 - 3.74 (m, 1H), 3.78 (dd, J =4.0, 10.5 Hz, 1H), 3.71 - 3.63 (m, 1H), 3.67 (d, J =6.5 Hz, 2H), 3.40 (br s, 4H), 3.35 - 3.22 (m, 8H), 3.20 - 3.03 (m, 1H), 3.01 - 2.73 (m, 6H), 2.64 - 2.49 (m, 1H), 2.09 (qd, J =6.4, 12.8 Hz, 1H). MS (ESI) m / z (M+ H) + =632.1. SFC holding time 7.708min.

[0259] Separation conditions: カラム: DAICEL CHIRALCEL OD-H (250mm×30mm, 5μm); カラム temperature: 35℃; mobile phase: CO2-メタノール (0.05%のDEA); メタノール: 5%~40% 5min, 40% 2.5min, 5% 2.5min; flow rate: 2.5mL / min. HPLC: retention time 4.54min.

[0260] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 50 mm; Column temperature: 40 °C; Mobile phase: water-acetonitrile; Acetonitrile: 0%~60% 4 min, 60% 2 min; Flow rate: 1.2 mL / min.

[0261] Synthesis of Example E2

[0262] [ka]

[0263] Step 1: Preparation of compound E2-1 Compound E1-8 (120 mg, 163.72 μmol) was dissolved in tetrahydrofuran (5 mL) and tetra-n-butylammonium fluoride (1 M, 0.2 mL) was added, followed by stirring at room temperature (20 ° C.) for 1 hour. After the reaction was completed, the mixture was diluted with ethyl acetate (50 mL), washed with saturated saline (30 mL × 2) and water (30 mL × 2), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound E2-1, which was used directly in the next step without further purification. 1 H NMR (400MHz, Chloroform-d) δ = 8.15 (br s, 2H), 7.23 (br dd, J =2.1, 13.1 Hz, 2H), 7.18 (br t, J =8.6 Hz, 2H), 6.69 (s, 1H), 5.37 (td, J =6.5, 12.9 Hz, 1H), 3.70 - 3.60 (m, 7H), 3.27 (br s, 4H), 3.18 - 2.99 (m, MS (ESI) m / z (M+1) + =619.3.

[0264] Step 2: Preparation of compound E2-2 Compound E2-1 (85 mg, 137.39 μmol) was dissolved in dichloromethane (5 mL), manganese dioxide (85 mg, 977.69 μmol) was added thereto, and the mixture was stirred at room temperature for 18 hours. The crude product was obtained by filtration and concentration under reduced pressure, and purified by medium pressure column chromatography (methanol / dichloromethane (v / v) = 0-5%) to obtain compound E2-2. MS (ESI) m / z (M+1) + =617.3.

[0265] Step 3: Preparation of compound E2 The following Example E2 was synthesized in a similar manner to the synthesis of Example A1. 1 H NMR (400MHz, Chloroform-d) δ = 8.13 (br s, 2H), 7.32 (br s, 1H), 7.17 (br t, J =8.5 Hz, 2H), 6.60 (s, 1H), 4.71 (br s, 1H), 4.44 (br s, 1H), 4.35 - 4.26 (m, 1H), 4.10 (br dd, J =3.3, 9.5 Hz, 1H), 3.91 (br d, J =14.6 Hz, 1H), 3.70 (s, 3H), 3.46 (br s, 4H), 3.20 (br t, J =5.9 Hz, 2H), 3.11 (s, 2H), 2.93 - 2.84 (m, 2H), 2.71 (br s, 4H), 2.42 (br s, 1H). MS (ESI) m / z (M+ H) + =630.1. HPLC retention time 3.7712min.

[0266] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 50 mm; Column temperature: 50 °C; Mobile phase: water (0.2 M / L ammonia water)-acetonitrile; Acetonitrile: 10% to 80% for 6 min, 80% for 2 min; Flow rate: 0.8 mL / min.

[0267] Synthesis of Example E3

[0268] [ka]

[0269] Compound E3-4 was synthesized from compound E3-1 in the same manner as in the synthesis of compound E2-3. Compound E3-4 (40 mg, 75.68 μmol) and (S)-tetrahydro-3-furan carboxylic acid (13.33 mg, 114.83 μmol) were dissolved in dichloromethane (3 mL) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (46.67 mg, 122.73 μmol) and triethylamine (48.47 mg, 478.97 μmol, 66.67 uL) were added and stirred at room temperature (25 ° C.) for 18 hours. After the reaction was completed, the mixture was diluted with water (20 mL), extracted with ethyl acetate (20 mL × 2), washed with saturated saline (20 mL × 2), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by preparative high performance liquid chromatography to obtain compound E3. 1 H NMR (400MHz, CHLOROFORM-d) δ = 8.16 (br s, 2H), 7.19 (t, J = 8.7 Hz, 2H), 6.82 (br d, J = 8.8 Hz, 1H), 6.19 - 6.11 (m, 1H), 4.40 (br s, 2H), 4.25 (br s, 6H), 4.00 - 3.80 (m, 4H), 3.70 (s, 3H), 3.26 - 3.17 (m, 2H), 2.96 - 2.89 (m, 3H), 2.17 (s, 1H), 2.08 (br s, 1H). MS (ESI) m / z (M+1)+=627.1. HPLC: Retention time 3.934min.

[0270] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 50 mm; Column temperature: 50 °C; Mobile phase: water (0.2 mL / 1 L of ammonia water)-acetonitrile; Acetonitrile: 10%~80% 6 min, 80% 2 min; Flow rate: 0.8 mL / min.

[0271] The following Example E4 was synthesized similarly to the synthesis of Example E3, and is as shown in Table 4 below.

[0272] [Table 4]

[0273] Synthesis of Example E5

[0274] [ka]

[0275] Step 1: Preparation of compound E5-1 Compound E5-1 was synthesized from compound E1-7 in the same manner as in the synthesis of compound E1-8. Step 2: Preparation of compound E5-2 Compound E5-2 was synthesized from compound E5-1 in the same manner as in the synthesis of compound E1-9.

[0276] Step 3: Preparation of compound E5-3 The synthesis was the same as that of compound E3.

[0277] Step 4: Preparation of compound E5 Compound E5 was synthesized from compound E5-3 in the same manner as in the synthesis of compound E1. 1H NMR (400MHz, CHLOROFORM-d) δ = 8.15 (br s, 2H), 7.18 (t, J = 8.5 Hz, 2H), 6.79 - 6.68 (m, 1H), 6.20 (s, 1H), 5.41 - 5.28 (m, 1H), 4.44 - 4.32 (m, 2H), 4.21 (s, 2H), 4.14 (br s, 4H), 4.02 - 3.95 (m, 1H), 3.94 - 3.88 (m, 1H), 3.87 - 3.76 (m, 2H), 3.63 (s, 3H), 3.35 (br s, 1H), 3.10 (dt, J = 4.5, 8.7 Hz, 1H), 2.97 - 2.84 (m, MS (ESI) m / z (M+1) + =629.1. HPLC retention time: 3.79min.

[0278] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 50 mm; Column temperature: 50 °C; Mobile phase: water (0.2 mL / 1 L of ammonia water)-acetonitrile; Acetonitrile: 10%~80% 6 min, 80% 2 min; Flow rate: 0.8 mL / min.

[0279] Step 5: Preparation of Compound E5-a or E5-b Compound E5 was purified by SFC to give compounds E5-a and E5-b. Compound E5-a: 1 H NMR (400MHz, CHLOROFORM-d) δ = 8.14 (br s, 2H), 7.18 (t, J = 8.5 Hz, 2H), 6.73 (br d, J = 11.8 Hz, 1H), 6.20 (s, 1H), 5.39 (br d, J = 6.0 Hz, 1H), 4 .37 (q, J = 8.6 Hz, 2H), 4.21 (s, 2H), 4.15 (br s, 4H), 3.99 (t, J = 8.2 Hz, 1H), 3.95 - 3.76 (m, 3H), 3.63 (s, 3H), 3.09 (br s, 1H), 2.98 - 2.83 (m, 2H), 2.72 - 2.58 (m, 1H), 2.25 - 2.12 (m, 2H), 2.11 - 2.02 (m, 1H). MS (ESI) m / z (M+ H) + =629.1. SFC holding time: 2.172min.

[0280] Separation conditions: カラム: Chiralpak AD-3 50mm×4.6mm ID, 3μm; カラム temperature: 35℃; mobile phase: CO2-エタノール (0.05%のDEA); エタノール: 5%~40% 2min, 40% 1.2min, 5% 0.8min; flow rate: 0.8mL / min. HPLC holding time: 3.769min.

[0281] Separation conditions: カラム: Xbridge Shield RP-18, 5μm, 2.1×50mm; カラム temperature: 50℃; mobile phase: water (0.2mL / 1L のアンモニアwater) - アセトニトリル; アセトニトリル: 10%~80% 6min, 80% 2min; flow rate: 0.8mL / min. Compound E5-b: 1 H NMR (400MHz, CHLOROFORM-d) δ = 8.14 (br s, 2H), 7.18 (br t, J = 8.4 Hz, 2H), 6.73 (br d, J = 11.3 Hz, 1H), 6.20 (s, 1H), 5.45 - 5.31 (m, 1H), 4.46 - 4.28 (m, 2H), 4.21 (br s, 2H), 4.14 (br s, 4H), 3.99 (br t, J = 7.8 Hz, 1H), 3.94 - 3.76 (m, 3H), 3.63 (s, 3H), 3.09 (br s, 1H), 2.98 - 2.83 (m, 2H), 2.70 - 2.59 (m, 1H), 2.26 - 1.98 (m, 3H). MS (ESI) m / z (M+ H) + =629.2. SFC retention time: 2.566min.

[0282] Separation conditions: Column: Chiralpak AD-3 50 mm × 4.6 mm ID, 3 μm; Column temperature: 35 °C; Mobile phase: CO2-ethanol (0.05% DEA); Ethanol: 5%-40% 2 min, 40% 1.2 min, 5% 0.8 min; Flow rate: 0.8 mL / min. HPLC retention time: 3.816 min.

[0283] Separation conditions: Column: Xbridge Shield RP-18, 5 μm, 2.1 × 50 mm; Column temperature: 50 °C; Mobile phase: water (0.2 mL / 1 L of ammonia water)-acetonitrile; Acetonitrile: 10%~80% 6 min, 80% 2 min; Flow rate: 0.8 mL / min.

[0284] Synthesis of Example E25

[0285] [ka]

[0286] Step 1: Preparation of compound E25-2 Compound E25-1 (8.0 g, 56.1 mmol) was dissolved in DMF (60 mL), cooled in an ice-water bath, and then NIS (16.4 g, 72.9 mmol) was added in batches, then allowed to warm to room temperature and stirred overnight. The reaction solution was poured into a saturated aqueous sodium sulfite solution (300 mL), extracted with EtOAc (300 mL x 2), and the organic phase was washed with saturated saline (200 mL x 2), dried, concentrated, and subjected to normal phase column chromatography EtOAc / PE = 0-25% to obtain the title compound E25-2 (8.2 g, light brown solid, yield: 54.3%). LC-MS (ESI): m / z [M+H] + : 269.0

[0287] Step 2: Preparation of compound E25-3 Compound E25-2 (4.1 g, 15.3 mmol) was dissolved in DMF (30 mL) at room temperature, zinc cyanide (1.97 g, 16.8 mmol) and Pd(PPh3)4 (0.88 g, 0.76 mmol) were added, and the mixture was stirred at 80 °C for 4 hours under nitrogen gas protection. The completion of the reaction was monitored by LC-MS, and the reaction solution was cooled to room temperature, poured into cold aqueous sodium bicarbonate solution (100 mL), added with ethyl acetate (100 mL), filtered through diatomaceous earth, rinsed with EtOAc, and the filtrate was extracted with ethyl acetate (200 mL x 2). The organic phase was washed with saturated brine (150 mL x 2), dried over anhydrous sodium sulfate, concentrated, and subjected to normal phase column chromatography (EtOAc / PE = 0-30%) to obtain the title compound E25-3 (2.25 g, yellow solid, yield: 87.9%). LC-MS (ESI): m / z [M+H] + : 168.2

[0288] Step 3: Preparation of compound E25-4 Compound E25-3 (2.0 g, 11.9 mmol) was dissolved in toluene (30 mL) at room temperature. The mixture was dissolved in toluene, p-toluenesulfonic acid (0.1 g, 0.6 mmol) and compound E1-1 (1.17 g, 11.9 mmol) were added, the temperature was raised to 170°C and refluxed, water was separated using a trap, and the reaction was carried out for 4 hours. The reaction solution was cooled, concentrated, and subjected to normal phase column chromatography (MeOH / DCM=0-5%) to obtain the title compound E25-4 (1.62 g, yellow solid, yield: 81.0%). LC-MS (ESI): m / z [M+H] + : 248.1

[0289] Step 4: Preparation of compound E25-5 At a temperature of -78°C, LiHMDS (17mL, 1.0M, 17mmol) was slowly added dropwise to the THF (16mL) of compound E25-4 (2.1g, 8.5mmol) protected with nitrogen gas, and the temperature was controlled below -60°C. After the addition was completed, the reaction system was stirred for 1 hour while controlling the temperature below -60°C, and the completion of the reaction was monitored by LC-MS. The reaction solution was poured into an aqueous ammonium chloride solution (20mL), a solid precipitated, filtered, the cake was rinsed with water, and the cake was dried naturally to obtain the title compound E25-5 (4.2g, crude product). LC-MS (ESI): m / z [M+H] + : 248.1

[0290] Step 5: Preparation of compound E25-6 At room temperature, NaBH4 (0.32 g, 8.5 mmol) was added in batches to the mixture of compound E25-5 (4.2 g, crude product) in MeOH (25 mL) and THF (25 mL), and after the addition was complete, the mixture was stirred at room temperature for 1 hour, and the reaction was monitored by LC-MS for completion. The reaction solution was concentrated to remove most of the solvent, and then half-saturated aqueous ammonium chloride solution was added, slurried at room temperature for about 10 minutes, filtered, the cake was rinsed with water, and the cake was taken and added with acetonitrile and concentrated to give the title compound E25-6 (1.34 g, gray solid, 2-step yield: 64.1%). LC-MS (ESI): m / z [M+H] + : 250.2

[0291] Step 6: Preparation of compound E25-7 At room temperature, TBSCl (3.14 g, 20.82 mmol) and imidazole (1.77 g, 26.0 mmol) were added to compound E25-6 (2.6 g, 10.4 mmol) in DMF (18 mL), stirred at room temperature overnight, and monitored the completion of the reaction by LC-MS. The reaction solution was poured into water, extracted with EtOAc, washed with saturated saline, dried, concentrated, and purified by column chromatography (EtOAc / PE=0-20%) to obtain the title compound E25-7 (2.87 g, gray solid, yield: 75.9%). LC-MS (ESI): m / z [M+H] + : 364.2

[0292] Step 7: Preparation of compound E25-8 In an ice bath, a solution of compound A1-3 (2.13 g, 5.85 mmol) in DMF (10 mL) was added dropwise to a dry DMF (5 mL) solvent of NaH (1.17 g, 29.25 mmol), and after completion of the addition, the mixture was stirred for about 30 minutes in an ice water bath. Then, a solution of compound E25-7 (1.82 g, 7.61 mmol) in DMF (10 mL) was added dropwise, and after completion of the addition, the mixture was allowed to warm to room temperature and stirred for 2 hours. The completion of the reaction was monitored by LC-MS, and the reaction solution was poured into water, extracted with EtOAc, the organic phase was concentrated, and the title compound E25-8 (2.18 g, pale yellow solid, yield: 65.9%) was obtained by column (EtOAc / PE=0-20%). LC-MS (ESI): m / z [M+H] + : 566.1.

[0293] Step 8: Preparation of compound E25-9 Potassium carbonate (1.17 g, 8.48 mmol) and MeI (0.6 g, 4.24 mmol) were added sequentially to a solution of compound E25-8 (1.2 g, 2.12 mmol) in DMF (8.0 mL) under an ice-water bath, and then the mixture was allowed to warm to room temperature and stirred for 2 hours. The completion of the reaction was monitored by LC-MS, and the reaction solution was added to water, extracted with EtOAc, and the organic phase was spin-dried and purified by column chromatography (EtOAc / PE=0-20%). The title compound E25-9 (1.15 g, green solid, yield: 93.5%) was obtained. LC-MS(ESI): m / z [M+H] + : 580.1

[0294] Step 9: Preparation of compound E25-10 Compound E25-9 (0.46 g, 0.79 mmol), compound tert-butyl 2,6-diazaspiro[3,3]heptane-2-carboxylate hemioxalate (0.46 g, 1.9 mmol), DIEA (0.46 g, 3.56 mmol) were added to NMP (2.5 mL), and the temperature was raised to 140 ° C. and reacted overnight. The completion of the reaction was monitored by LC-MS. The reaction solution was poured into water (20 mL), a solid precipitated, filtered, the cake was taken and dissolved by adding ethyl acetate, and then washed once with saturated saline. The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (EtOAc / PE = 0 ~ 30%) to obtain the title compound E25-10 (0.36 g, pale yellow solid, yield: 61.0%). LC-MS (ESI): m / z [M + H] + : 742.3

[0295] Step 10: Preparation of compound E25-11 At room temperature, 6N hydrochloric acid (8.0mL) was added to a solution of compound E25-10 (1.5g, 2.02mmol) in methanol (10mL), the reaction system was stirred at room temperature overnight, and the completion of the reaction was monitored by LC-MS. Saturated aqueous sodium bicarbonate solution was slowly added to the reaction solution to adjust the pH to basic, and the mixture was extracted with DCM. The organic phase was concentrated and purified by column chromatography (MeOH / DCM=0~10%) to obtain the title compound E25-11 (0.74g, pale yellow solid, yield: 69.1%). LC-MS(ESI): m / z [M+H] + : 528.1.

[0296] Step 11: Preparation of compound E25-12 Compound E25-11 (1.11 g, 2.1 mmol), 2-hydroxyisobutyric acid (0.24 g, 2.31 mmol) were added to a reaction flask containing DMF (8.0 mL), cooled in an ice-water bath, HATU (0.96 g, 2.53 mmol) and DIEA (0.68 g, 5.25 mmol) were added thereto, and then the ice-water bath was removed and stirred at room temperature for about 3 hours. The reaction solution was added to water, extracted twice with EtOAc, washed with brine, and the organic phase was dried, concentrated, and purified by column chromatography (MeOH / DCM=0-5%) to obtain the title compound E25-12 (1.03 g, pale yellow solid, yield: 79.8%). LC-MS (ESI): m / z [M+H] + : 614.7.

[0297] Step 12: Preparation of compound E25-13 Under nitrogen gas protection, compound E25-12 (1.14 g, 1.86 mmol) was dissolved in DCM (12 mL), and after ice-water bath, DMP (1.18 g, 2.79 mmol) was added in batches, and the reaction system was warmed to room temperature and stirred for 4 hours. The completion of the reaction was monitored by LC-MS, and the reaction solution was slowly added to aqueous sodium bicarbonate solution (20 mL), foaming occurred, and extracted with DCM, and the organic phase was washed with brine, dried, concentrated, and purified by normal phase column chromatography (MeOH / DCM=0~2%) to obtain the title compound E25-13 (0.66 g, pale yellow solid, yield: 58.4%). LC-MS (ESI): m / z [M+H] + : 612.2.

[0298] Step 13: Preparation of compound E25 Compound E25-13 (0.53 g, 0.87 mmol) was dissolved in dry THF (7.5 mL), and methylmagnesium bromide (1.16 mL, 3.0 M, 3.48 mmol) was added dropwise at -20 °C. After the addition was completed, the mixture was allowed to warm to room temperature and stirred overnight. The reaction solution was poured into a cold ammonium chloride solution (10 mL), extracted twice with EtOAc, the organic phase was concentrated, and the crude product was obtained by column chromatography (MeOH / DCM = 0-2%). The crude product was purified by preparative column chromatography (preparation method: mobile phase: A: 0.05% ammonia water; B: acetonite; C: 1.0% ethyl acetate; D: 1.0% ethyl acetate; E: 1.0% ethyl acetate; F: 1.0% ethyl acetate; H: 1.0% ethyl acetate; I ... Trill; column: XBridge C18, 19 x 250 mm x 10 um, flow rate: 20 ml / min, column temperature: 25 °C; gradient: 51% to 51%, collected from 8.6 min to 9.6 min) to give the title compound E25 (light yellow solid, 52 mg, yield: 9.6%).

[0299] Step 14: Preparation of Compounds E25-a and E25-b Compound E25 was purified by SFC to give compounds E25-a and E25-b.

[0300] In the same manner as in the synthesis of Examples E1, E2, E3, E5, and E25, Examples E6 to E24 were synthesized, and Examples E26 to E66 were synthesized, as shown in Table 5 below.

[0301] [Table 5] TIFF2024543167000138.tif235159TIFF2024543167000139.tif236159TIFF2024543167000140.tif235159TIFF2024543167000141.tif236159TIFF2024543167000142.tif236159TIFF2024543167000143.tif235159TIFF2024543167000144.tif236159TIFF2024543167000145.tif236159TIFF2024543167000146.tif236159TIFF2024543167000147.tif235159TIFF2024543167000148.tif235159TIFF2024543167000149.tif236159TIFF2024543167000150.tif236159TIFF2024543167000151.tif235159TIFF2024543167000152.tif215159TIFF2024543167000153.tif235159TIFF2024543167000154.tif235159TIFF2024543167000155.tif235159TIFF2024543167000156.tif235159TIFF2024543167000157.tif236159TIFF2024543167000158.tif237159TIFF2024543167000159.tif237159TIFF2024543167000160.tif237159TIFF2024543167000161.tif237159TIFF2024543167000162.tif237159TIFF2024543167000163.tif237159TIFF2024543167000164.tif237159TIFF2024543167000165.tif238159TIFF2024543167000166.tif238159TIFF2024543167000167.tif238159TIFF2024543167000168.tif237159TIFF2024543167000169.tif237159TIFF2024543167000170.tif238159TIFF2024543167000171.tif238159TIFF2024543167000172.tif238159TIFF2024543167000173.tif229159TIFF2024543167000174.tif230159TIFF2024543167000175.tif238159TIFF2024543167000176.tif238159TIFF2024543167000177.tif238159TIFF2024543167000178.tif238159TIFF2024543167000179.tif189159TIFF2024543167000180.tif237159TIFF2024543167000181.tif238159TIFF2024543167000182.tif217159TIFF2024543167000183.tif239159TIFF2024543167000184.tif238159TIFF2024543167000185.tif217159TIFF2024543167000186.tif238159TIFF2024543167000187.tif238159TIFF2024543167000188.tif238159TIFF2024543167000189.tif231159TIFF2024543167000190.tif238159TIFF2024543167000191.tif232159TIFF2024543167000192.tif238159TIFF2024543167000193.tif232159TIFF2024543167000194.tif237159TIFF2024543167000195.tif232159TIFF2024543167000196.tif238159TIFF2024543167000197.tif238159TIFF2024543167000198.tif218159TIFF2024543167000199.tif238159TIFF2024543167000200.tif189159TIFF2024543167000201.tif237159TIFF2024543167000202.tif237159TIFF2024543167000203.tif224159TIFF2024543167000204.tif237159TIFF2024543167000205.tif238159TIFF2024543167000206.tif238159TIFF2024543167000207.tif225159TIFF2024543167000208.tif238159TIFF2024543167000209.tif232159TIFF2024543167000210.tif231159TIFF2024543167000211.tif237159TIFF2024543167000212.tif237159TIFF2024543167000213.tif232159TIFF2024543167000214.tif232159TIFF2024543167000215.tif232159TIFF2024543167000216.tif218159TIFF2024543167000217.tif237159TIFF2024543167000218.tif238159TIFF2024543167000219.tif190159TIFF2024543167000220.tif238159TIFF2024543167000221.tif238159TIFF2024543167000222.tif238159TIFF2024543167000223.tif238159TIFF2024543167000224.tif238159TIFF2024543167000225.tif238159TIFF2024543167000226.tif231159TIFF2024543167000227.tif237159TIFF2024543167000228.tif231159TIFF2024543167000229.tif238159TIFF2024543167000230.tif238159TIFF2024543167000231.tif238159TIFF2024543167000232.tif231159TIFF2024543167000233.tif238159. TIFF2024543167000234.tif238159TIFF2024543167000235.tif225159

[0302] Synthesis of Example F1 The following compound F1-1 was synthesized in the same manner as in Example A1. MS (ESI) m / z (M+H) + = 575.0.

[0303] [ka]

[0304] Step 1: Preparation of compound F1-2 Compound F1-1 (57.0 mg, 0.1 mmol) and lithium hydroxide (50.0 mg) were dissolved in a mixed solvent of tetrahydrofuran (3.0 mL) and water (1.0 mL) and stirred at 50°C for 1 hour. After the reaction was completed, the crude product was purified using a reverse phase chromatography separation column [water (10.0 mM / L ammonium bicarbonate solution)-acetonitrile: 20% to 60%] to obtain compound F1-2. MS (ESI) m / z (M+ H) + = 547.0.

[0305] Step 2: Preparation of compound F1 Compound F1-2 (30.0 mg, 0.055 mmol) and 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (43.0 mg, 0.082 mmol) were dissolved in N,N-dimethylformamide (1.0 mL) and N,N-diisopropylethylamine (14.0 mg, 0.11 mmol) was added and stirred at room temperature (25° C.) for 15 minutes. Then, hydroxylamine hydrochloride (7.7 mg, 0.11 mmol) was added to the reaction system and the mixture was stirred for 1.0 hour. After the reaction was completed, the crude reaction product was purified by preparative high performance liquid chromatography (separation conditions: column: Welch Xtimate (registered trademark) C18, 21.2 × 250 mm; column temperature: 25 ° C; mobile phase: [water (10.0 mM / L ammonium bicarbonate solution) - acetonitrile]; mobile phase acetonitrile ratio: 50% to 80% 9 min; flow rate: 30.0 mL / min.) to obtain compound F1. 1H NMR (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 8.72 (s, 1H), 8.04 - 7.90 (m, 2H), 7.44 (dd, J = 14.2, 2.6 Hz, 1H), 7.38 - 7.29 (m, 2H), 6.73 (d, J = 2.5 Hz, 1H), 3.56 (s, 3H), 3.48 (t, J = 5.1 Hz, 2H), 3.21 (d, J = 5.3 Hz, 4H), 3.19 - 3.12 (m, 3H), 2.86 (s, 2H), 2.51 (d, J = 5.0 Hz, 4H). MS (ESI) m / z (M+ H)+= 562.0. HPLC: Purity: 98.8%; Retention time: 5.56min.

[0306] Separation conditions: Column: Waters XBridge, 4.6×100 mm, 3.5 μm; Column temperature: 40°C; Mobile phase: water (10 mM NH4HCO3)-acetonitrile; Acetonitrile: 5%~95% 7 min; 95% 8 min Flow rate: 1.2 mL / min. Synthesis of Example F2

[0307] [ka]

[0308] Step 1: Preparation of compound F2-2 Compound F2-1 (1 g, 4.74 mmol) was dissolved in methanol (10 mL) and sodium borohydride (540 mg, 14.22 mmol) was added in batches and stirred at room temperature (25 ° C) for 2 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (80 mL × 3). The organic phases were combined and washed with saturated sodium chloride (200 mL × 2), then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound F2-2, which was used directly in the next step without further purification. MS (ESI) m / z (M + H) + -56 = 158.0

[0309] Step 2: Preparation of compound F2-3 Compound F2-2 (1 g, 4.74 mmol) was dissolved in dichloromethane (15 mL), and a solution of hydrochloric acid in dioxane (2 mL) was added and stirred at room temperature (25° C.) for 6 hours. The reaction solution was concentrated under reduced pressure to obtain compound F2-3, which was used directly in the next step without further purification. MS (ESI) m / z (M+ H) + = 114.0.

[0310] Step 3: Preparation of compound F2 Compound F2-3 (50 mg, 0.0915 mmol), compound F1-2 (51 mg, 0.457 mmol), 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (52 mg, 0.137 mmol) and N,N-diisopropylethylamine (35.3 mg, 0.274 mmol) were dissolved in N,N-dimethylformamide (1 mL) and stirred at room temperature (25 ° C) for 2 hours. The reaction crude product was purified by preparative high performance liquid chromatography (separation conditions: column: Welch Xtimate C18, 250 × 21.2 mm; column temperature: 25 ° C; mobile phase: water (10 mM / L NH4HCO3) - acetonitrile; acetonitrile: 20% to 40% 12 min, flow rate: 30 mL / min) to obtain compound F2. 1 H NMR (400 MHz, DMSO-d6) δ 8.04 (dd, J = 8.6, 5.5 Hz, 2H), 7.51 (d, J = 14.2 Hz, 1H), 7.41 (t, J = 8.9 Hz, 2H), 6.8 (s, 1H), 5.02 (d, J = 6.2 Hz, 1H), 4.11 (d, J = 19.8 Hz, 2H), 3.94 (dd, J = 15.0, 7.9 Hz, 1H), 3.78 (d, J = 19.8 Hz, 2H), 3.63 (s, 3H), 3.59 - 3.50 (m, 2H), 3.29 - 3.25 (m, 4H), 3.23 (s, 2H), 2.97 (s, 2H), 2.54 (s, 2H), 2.36 (s, 4H), 1.93 (t, J = 9.0 Hz, 2H). MS (ESI) m / z (M+ H) + = 642.0 HPLC 100%. Retention time: 5.672min.

[0311] Separation conditions: Column: Waters XBridge, 4.6 × 100 mm, 3.5 μm; Column temperature: 40 °C; Mobile phase: A: water (10 mM ammonium bicarbonate) B: acetonitrile, acetonitrile: 5% to 95% 7 min; Flow rate: 1.2 mL / min.

[0312] The following F3 to F5 were synthesized in the same manner as in Example F2, and the results are shown in Table 6. It is.

[0313] [Table 6] TIFF2024543167000239.tif237160TIFF2024543167000240.tif175160

[0314] Example 4 Biological activity test 1. Preparation and treatment of compounds Compound stock solutions All compounds were prepared as 10 mM stock solutions in DMSO. The positive control compound GLPG1690 was prepared as a 10 mM stock solution in DMSO.

[0315] Compound storage The stock solution in DMSO was aliquoted and stored at -20°C. 2. Preparation of the experiment Preparation of 1x Assay Buffer: Solutions of pH 8.5 and pH 7.5 were prepared, respectively, with the following formulations:

[0316] 50 mM Tris, 10 mM CaCl2, 5 mM MgCl2, 0.02% Brij-35 (w / v). Preparation of 10x compound dilutions: All compounds, including the positive control compound, were first diluted 5-fold in DMSO from 10 mM to 2 mM, and then diluted to 100 μM in 1× Assay buffer.

[0317] Preparation of 100U / ml Choline Oxidase stock solution: 1x Reaction buffer was prepared by thoroughly mixing 1x volume of 5x Reaction buffer and 4x volume of double distilled water. Choline oxidase was dissolved in 1x Reaction buffer. The mixture was divided into small portions and frozen at -20℃.

[0318] Preparation of 200U / ml HRP (horseradish peroxidase) stock solution: 1x volume of 5x Reaction buffer and 4x volume of double distilled water were mixed thoroughly to prepare 1x Reaction buffer. HRP was dissolved in 1x Reaction buffer. The mixture was divided into small portions and frozen at -20℃.

[0319] Preparation of 10 mM Amplex® UltraRed reagent (detection reagent) stock solution: Amplex UltraRed reagent and DMSO were equilibrated to room temperature. One tube of Amplex UltraRed reagent (1 mg / tube) was dissolved in 340 μL of DMSO.

[0320] 3. Compounds were detected individually in 1× Assay buffer at two pH values: a) Using an electronic pipette, add 5 μL of 10x compound dilutions to a 384-well plate (Greiner 781209) (see "Experimental Preparation" step). Add 5 μL of 1x Assay buffer containing 5% DMSO to both negative and positive control wells. Centrifuge at 300 rpm for 1 minute at room temperature.

[0321] b) 2xATX (4ng / μL) was prepared in 1xAssay buffer and 25μL was added to the plate using an electronic pipette. 25μL of 1xAssay buffer was added to the negative control wells and 25μL of 2xATX was added to the positive control wells. Centrifuge at 300rpm for 1 minute at room temperature.

[0322] The plate was incubated at room temperature for 10 minutes. c) A 2.5x working solution was prepared using 1x Assay buffer containing Amplex UltraRed reagent (125μM), HRP (2.5U / ml), choline oxidase (1.25U / ml) and 16:0 Lyso PC (75μM). 20μL of the 2.5x working solution was added to all reaction wells using an electronic pipette. The wells were centrifuged at 300rpm for 1min at room temperature.

[0323] d) The plates were detected using Spectramax with the following program: Fluorescence mode, Excitation at 550 nm, Emission at 590 nm, Kinetics, one read every 2 minutes, continuous reading for 60 minutes.

[0324] 4. Data analysis: The formula for calculating %Inhibition (i.e., % inhibition rate) is as follows:

[0325]

number

[0326] V0: X-axis is 0-30 min, Y-axis is fluorescence reading, the software used is Graphpad prism 8, the slope corresponding to the fitted line is the initial reaction velocity.

[0327]

number

[0328] 5. IC 50 Calculation of and dose-response curve for compound: The IC of the compound was calculated from a nonlinear regression line (dose-initial reaction rate) fitted by the % inhibition rate and the log value of the compound concentration. 50 was calculated and the software used was Graphpad prism 8.

[0329] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)×Hill Slope)) X: Log value of inhibitor concentration Y:% inhibition The biological data results are shown in Table 7.

[0330] [Table 7] TIFF2024543167000244.tif235159TIFF2024543167000245.tif235159TIFF2024543167000246.tif200160

[0331] Example 5 Biological activity test Compound preparation and processing Compound stock solutions All compounds, including the positive control GLPG1690, were prepared as 10 mM stock solutions in DMSO.

[0332] Compound storage The stock solution in DMSO was aliquoted and stored at -20°C. Experimental preparation Aliquoting and cryopreservation of human / mouse plasma: The collected plasma was centrifuged at 4000 rpm at 4°C for 15 min, and the supernatant was dispensed into 96-well plates (25 μL per well), sealed and stored frozen at -80°C for later use.

[0333] A 2.5 μm 50XLPA 17:0 (lysophosphatidic acid 17:0, Sigma 857127P) stock solution (internal standard) was prepared. LPA17:0 powder was dissolved in a mixture of water:isopropyl alcohol:formic acid (1:1:1) to a final concentration of 2.5 μ m and stored frozen at −20°C in aliquots.

[0334] Preparation of 0.1% FA stock solution: One volume of formic acid was mixed homogeneously in 1000x methanol and stored at 4°C. Experimental steps: a) The 96-well plate containing frozen plasma was removed from the -80°C refrigerator and placed on ice at room temperature to thaw.

[0335] b) 6 μL of 50X LPA 17:0 (internal standard) and 264 μL of 0.1% FA were added to a clean 96-well plate well, resulting in a final concentration of 50 nM LPA 17:0 (internal standard).

[0336] c) A total of eight concentration gradients of 6x compounds were prepared with 1:3 gradient dilutions, and 5uL of compound was added to each well of the 96-well plate containing plasma. The maximum final concentration of compound was 10μM, and the final concentration of DMSO was 0.1%. Centrifuged at 300rpm for 30 seconds. The DMSO control sample reacted for 0 hours was used as the minimum value (Min), and the DMSO control sample reacted for 2 hours was used as the maximum value (Max).

[0337] d) The 0 time sample of DMSO was quickly transferred into the 0.1% FA solution containing the internal standard from step b) to stop the reaction and precipitate the plasma proteins. e) The 96-well plate containing plasma and compounds was quickly placed in a 37°C incubator and incubated for 2 hours. After incubation, 6 μL of 10XLPA 17:0 and 264 μL of 0.1% FA were added to each well to stop the reaction and precipitate plasma proteins.

[0338] f) All samples were mixed uniformly with a pipette, centrifuged at 4000 rpm at 4°C for 10 minutes, and 150 uL of the supernatant was taken into a 96-well U-bottom plate (Thermo 267245), sealed with silica gel to load the samples, and the contents of LPA18:1 and LPA18:2 in the samples were detected using an LC-MS / MS system.

[0339] Data Analysis: LPA18:1 (or 18:2) relative content = LPA18:1 (or 18:2) peak area / LPA17:0 peak area.

[0340] Plasma LPA18:1(or 18:2) reduction rate (%)=(Max-X) / (Max-Min)×100. Max: DMSO 2-hour sample LPA 18:1 (or 18:2) relative content Min:DMSO 0-hour sample LPA18:1 (or 18:2) relative content X: Relative LPA 18:1 (or 18:2) content in samples treated with compounds for 2 hours Compound dose-effect curves and IC 50 Calculation of: The IC of the compound was calculated by nonlinear regression fitting of the plasma LPA18:1 (or 18:2) reduction rate and the logarithm of the compound concentration. 50 was calculated and the software used was Graphpad Prism 8.

[0341] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)×Hill Slope)) X: Log value of inhibitor concentration Y: Plasma LPA18:1 (or 18:2) reduction rate The results are shown in Table 8.

[0342] [Table 8] TIFF2024543167000248.tif236159TIFF2024543167000249.tif235159TIFF2024543167000250.tif185159

[0343] Example 6 Pharmacokinetic study in mice Preparation: Dosing solutions were prepared on the day. 2 mg of compound was weighed and dissolved in 5% DMSO + 10% solutol + 85% saline to prepare an intravenous solution with a concentration of 0.2 mg / mL. 2 mg of compound was weighed and dissolved in 25% PEG200 + 75% (0.5% MC) to obtain an oral solution with a concentration of 1 mg / mL.

[0344] Six healthy male naive ICR mice weighing 25-30g were divided into two groups (intravenous administration group and oral administration group) with 3 mice / group, and administered a single dose. After acclimation for 3 days, the mice were fasted overnight (10-12 hours) the night before the experiment, allowed to drink water freely during the experiment, and resumed eating 4 hours after administration. After intravenous and oral administration, timing was started, and blood was collected through the orbital venous plexus at the planned time points (IV&PO 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 24h), and 40μL of whole blood was collected from each point into a 1.5mL EP tube containing sodium heparin, and the collected whole blood was mixed in a vortex mixer. The mixture was mixed homogenously by shaking twice at 4°C, placed on wet ice, and centrifuged at 8000 rpm for 5 min at 4°C within 1 h. The supernatant plasma was collected and stored in a -80°C refrigerator until processing and analysis.

[0345] [Table 9] TIFF2024543167000252.tif233160

Claims

1. A compound represented by formula (I), an optical isomer thereof, or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (however, Ring A is selected from cycloalkyl, heterocyclyl, and heteroaryl; Ring B is selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl; Ring C is selected from aryl and heteroaryl; Ring D is selected from aryl, heteroaryl, cycloalkyl, and heterocyclyl; X 1 is C(R 7a ) and N; X 2 is C(R 7b ) and N; X 3 is C(R 7c ) and N; X 4 is C(R 7d ) and N; L 1 is a single bond, NR 8 , O, S and C 1-6 alkyl, R 1 are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, OH, hydroxyalkyl, cyano, amino, nitro, carboxy, aldehyde, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R 2 are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxy, aldehyde, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R 3 is selected from H, alkyl, cycloalkyl, and heterocyclyl, wherein said alkyl, cycloalkyl, and heterocyclyl are each independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, carboxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R 4 are each independently H, halogen, alkyl, haloalkyl, heteroalkyl, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, -COOR 9 , aryl and heteroaryl, wherein said alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R 5 are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxy, aldehyde, OH, hydroxyalkyl, oxo, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently selected from halogen, alkyl, alkoxy, cyano, amino, nitro, carboxy, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl. optionally substituted with one or more substituents selected from aryl; R 6 Ha-ML 2 -R a and M is selected from a single bond or an alkyl, said alkyl being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, carboxy, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; L 2 is a single bond, -C(=O)-, -C(=O)O-, -C(=O)NR b --, --NR b C(=O)-, -NR b C(=O)O-, -O-, -OC(=O)-, -C(=O)-C(=O)-, -C(=O)-C(=O)NR b --, --NR b -, -S(=O) 2 -, -S(=O) 2 N.R. b - and -NR b S (=O) 2 - selected from R a is H, -S(O) 2 R c , alkyl, -NR b R c , cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, oxo, cyano, amino, nitro, carboxy, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R b is selected from H, OH, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl; R c is selected from H and alkyl; R 7a , R 7b , R 7c , R 7d are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; R 8 is selected from H, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl; R 9 is selected from H, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl; n is 0, 1, 2, 3 or 4; y is 0, 1, 2 or 3; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3.

2. A compound represented by formula (II), an optical isomer thereof, or a pharma- ceutically acceptable salt thereof. 【Chemistry 2】 (however, q is 0, 1, 2 or 3; X 5 is O, S, N (R 4a ), C(R 4a ) 2 and C=O; X 6 is O, S, N (R 4b ), C(R 4b ) 2 and C=O; X 7 are each independently N(R 4c ), C(R 4c ) 2 and C=O; 【Chemistry 3】 represents a double bond or a single bond, And X 5 and X 6 Between 【Chemistry 4】 When represents a double bond, X 5 is N and C(R 4a ), and X 6 is N and C(R 4b ) are selected from And X 6 is not simultaneously linked to two double bonds, R 4a , R 4b , R 4c are each independently H, halogen, alkyl, haloalkyl, heteroalkyl, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, -COOR 9 , aryl and heteroaryl, wherein said alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; Ring B, Ring C, Ring D, R 1 , R 2 , R 3 , R 5 , R 6 , X 1 , X 2 , X 3 , X 4 , n, m, y are as defined in claim 1.

3. A compound represented by formula (III), an optical isomer thereof, or a pharma- ceutically acceptable salt thereof: 【Chemistry 5】 (however, X 8 are each independently O, S, or N (R 2a ), —N═CH—, —CH═N—, and —CH═CH; X 9 are each independently C(R 2b ) and N; R 2a , R 2b are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxy, aldehyde, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; Ring B, Ring D, R 1 , R 3 , R 5 , R 6 , X 1 , X 2 , X 3 , X 4 , n, m are as defined in claim 1; X 5 、X 6 、X 7 、q、 【Chemistry 6】 is as defined in claim 2.

4. Ring A is C 4-8 The compound according to claim 1, an optical isomer thereof or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from cycloalkyl, 4- to 8-membered heterocyclyl and 5- to 6-membered heteroaryl.

5. Ring A is C 4-6 The compound according to claim 1, an optical isomer thereof or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from cycloalkyl, 5- to 6-membered heterocyclyl and 5- to 6-membered heteroaryl.

6. The compound according to claim 1, its optical isomer or its pharma- ceutically acceptable salt, wherein Ring A is selected from cyclobutyl, cyclopentyl, tetrahydrofuranyl, pyrrolidinyl, cyclopentanone, dihydrofuran-2(3H)-one, pyrrolidin-2-one, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl and 1,2,3-oxadiazolyl.

7. R 4 are each independently H, OH, C 1-6 Alkyl and C 1-6 heteroalkyl, wherein said C 1-6 Alkyl and C 1-6 2. The compound of claim 1, its optical isomer or a pharma- ceutically acceptable salt thereof, wherein heteroalkyl is optionally substituted with one or more of OH, amino, halogen.

8. R 4a , R 4b , R 4c are each independently H, OH, or C 1-6 Alkyl and C 1-6 heteroalkyl, wherein said C 1-6 Alkyl and C 1-6 3. The compound of claim 2, its optical isomer or a pharma- ceutically acceptable salt thereof, wherein heteroalkyl is optionally substituted with one or more of OH, amino, halogen.

9. Structural Units 【Chemistry 7】 but, 【Chemistry 8】 The compound according to claim 1, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from:

10. Ring B is phenyl, 5- to 6-membered heteroaryl, C 3-6 The compound according to any one of claims 1 to 3, which is selected from cycloalkyl, 5- to 6-membered heterocyclyl, benzo 5- to 6-membered heterocyclyl, and 5- to 9-membered bicycloalkyl, its optical isomer, or a pharma- ceutically acceptable salt thereof.

11. The compound according to claim 10, an optical isomer thereof or a pharma- ceutically acceptable salt thereof, wherein ring B is selected from phenyl, pyridyl, cyclohexyl, tetrahydro-2H-pyranyl, benzo[d][1,3]dioxazolyl and bicyclo[1.1.1]pentyl.

12. Structural Units 【Chemistry 9】 but, 【Chemistry 10】 The compound according to any one of claims 1 to 3, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

13. Ring D is phenyl, 5- to 6-membered heteroaryl, C 3-6 The compound according to any one of claims 1 to 3, wherein the compound is selected from cycloalkyl and 6- to 10-membered heterocyclyl, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.

14. The compound according to claim 13, wherein Ring D is selected from piperazinyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[4.4]nonyl, 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[3.5]nonyl, 2,5-diazabicyclo[2.2.1]heptyl and octahydropyrrolo[3,4-c]pyrrolyl, an optical isomer thereof, a pharmaceutical isomer thereof or a pharma- ceutically acceptable salt thereof.

15. Ring D 【Chemistry 11】 15. The compound according to claim 14, an optical isomer thereof, a pharmaceutical isomer thereof or a pharma- ceutically acceptable salt thereof, selected from:

16. R 6 Ga-C 1-3 Alkyl-C(═O)-3 to 9-membered heterocyclyl, —C 1-3 Alkyl-C(═O)-3- to 9-membered heterocyclyl-C 1-6 Alkyl, -C(=O)-3 to 9 membered heterocyclyl, -C(=O)-C 3-9 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C 1-3 Alkyl-C(=O)-NH-C 1-6 Alkyl, -S(=O) 2 -C 1-3 Alkyl and -C 1-3 alkyl-C(═O)NH—OH, 1-3 Alkyl-C(═O)-3 to 9-membered heterocyclyl, —C 1-3 Alkyl-C(═O)-3- to 9-membered heterocyclyl-C 1-6 Alkyl, -C(=O)-5 to 6-membered heterocyclyl, -C(=O)-C 3-9 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C 1-3 Alkyl-C(=O)-NH-C 1-6 Alkyl, -S(=O) 2 -C 1-3 Alkyl or -C 1-3 The compound according to any one of claims 1 to 3, wherein alkyl-C(=O)NH-OH is optionally substituted by one, two or three of OH, amino, methyl, ethyl, hydroxymethyl, trifluoromethyl, methoxy, or halogen, its optical isomer or a pharma- ceutically acceptable salt thereof.

17. R 6 but, 【Chemistry 12】 and 【Chemistry 13】 is optionally substituted by one, two or three of OH, methyl, ethyl, hydroxymethyl or halogen, an optical isomer thereof or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 3.

18. R 6 but, 【Chemistry 14】 18. The compound according to claim 17, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from:

19. Structural Units 【Chemistry 15】 but, 【Chemistry 16】 【change】 The compound according to any one of claims 1 to 3, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

20. R 3 H, C 1-6 Alkyl, C 3-6 cycloalkyl and 4- to 6-membered heterocyclyl, 1-6 Alkyl, C 3-6 Cycloalkyl or 4- to 6-membered heterocyclyl is selected from the group consisting of halogen, cyano, amino, C 1-6 The compound according to any one of claims 1 to 3, optionally substituted with one, two or three alkyl groups, its optical isomer or a pharma- ceutically acceptable salt thereof.

21. R 3 is H, methyl, ethyl, 【Chemistry 17】 The compound according to any one of claims 1 to 3, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

22. The compound according to claim 1 or 2, its optical isomer or its pharma- ceutically acceptable salt, wherein Ring C is selected from 5-6 membered heteroaryl, and the heteroaryl contains 1 to 3 heteroatoms selected from N atoms, O atoms or S atoms.

23. R 7a , R 7b , R 7c , R 7d are each independently H, halogen, or C 1-6 Alkyl, C 1-6 Alkoxy, cyano, amino, nitro, OH, C 3-6 cycloalkyl, 5- to 6-membered heterocyclyl, phenyl, and 5- to 6-membered heteroaryl; 1-6 2. The compound according to claim 1, an optical isomer thereof or a pharma- ceutically acceptable salt thereof, wherein the alkyl is optionally substituted with one, two or three halogens.

24. Structural Units 【Chemistry 18】 but, 【Chemistry 19】 24. The compound according to claim 1, 7 or 23, an optical isomer thereof or a pharma- ceutically acceptable salt thereof, selected from:

25. Structural Units 【Chemistry 20】 but, 【Chemistry 21】 The compound according to claim 1 or 7, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from:

26. A compound of the following formula, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from the following formulas: 【Chemical 22】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】

27. A compound of the following formula, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, selected from the following formulas: 【Chemistry 23】

28. 30. Use of a compound according to any one of claims 1 to 27, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for treating an ATX-associated disease.

29. Cancer, metabolic diseases, kidney diseases, liver diseases, fibrotic diseases, inflammatory diseases, pain, autoimmune diseases, 29. The ATX-related disease of claim 28, selected from respiratory diseases, cardiovascular diseases, neurodegenerative diseases, myelodysplastic syndromes, obesity, skin diseases, and / or diseases associated with abnormal angiogenesis.

30. 30. The fibrotic disease of claim 29, selected from pulmonary fibrosis, renal fibrosis, and hepatic fibrosis.

31. 31. The pulmonary fibrosis of claim 30, selected from idiopathic pulmonary fibrosis and non-idiopathic pulmonary fibrosis.

32. 30. The liver disease of claim 29, selected from non-alcoholic steatohepatitis.

33. 30. The inflammatory disease of claim 29, selected from enteritis and osteoarthritis.

34. 30. The autoimmune disease of claim 29, selected from rheumatoid arthritis and multiple sclerosis.

35. 30. The respiratory disease of claim 29, selected from interstitial lung disease, asthma, and COPD.

36. 30. The cardiovascular disease of claim 29, selected from vascular injury, atherosclerosis, blood clotting.

Citation Information

Patent Citations

  • Benzonaphthyridineamine as an autotaxin inhibitor

    JP2013523607A

  • Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

    JP2016512208A

  • Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

    JP2016525072A

  • Aromatic heterocyclic compounds and pharmaceutical compositions thereof

    JP2021524475A